{ "version": "2.2", "instance": { "adxn-20251231x20f.htm": { "nsprefix": "adxn", "nsuri": "http://addextherapeutics.com/20251231", "dts": { "schema": { "local": [ "adxn-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "adxn-20251231_cal.xml" ] }, "definitionLink": { "local": [ "adxn-20251231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "adxn-20251231_lab.xml" ] }, "presentationLink": { "local": [ "adxn-20251231_pre.xml" ] }, "inline": { "local": [ "adxn-20251231x20f.htm" ] } }, "keyStandard": 341, "keyCustom": 178, "axisStandard": 34, "axisCustom": 3, "memberStandard": 51, "memberCustom": 60, "hidden": { "total": 51, "http://addextherapeutics.com/20251231": 42, "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 6, "http://xbrl.sec.gov/dei/2025": 3 }, "contextCount": 436, "entityCount": 1, "segmentCount": 119, "elementCount": 918, "unitCount": 13, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 1167, "http://xbrl.sec.gov/dei/2025": 47, "http://xbrl.sec.gov/cyd/2025": 15, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R2": { "role": "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:Assets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R3": { "role": "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss", "longName": "995200200 - Statement - Consolidated Statements of Profit or Loss", "shortName": "Consolidated Statements of Profit or Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_wKE5Vp0bX0GzjK5p_asUOQ", "name": "ifrs-full:FinanceIncome", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R4": { "role": "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss", "longName": "995200300 - Statement - Consolidated Statements of Comprehensive Profit or Loss", "shortName": "Consolidated Statements of Comprehensive Profit or Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansContinuingOperations", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R5": { "role": "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "longName": "995200400 - Statement - Consolidated Statements of Changes in Equity", "shortName": "Consolidated Statements of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_l9lkcN1BNUqkT6418CtYEQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_l9lkcN1BNUqkT6418CtYEQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R6": { "role": "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200500 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:AdjustmentsForIncomeOfFairValueOfServicesReceivedAtZeroCost", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R7": { "role": "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical", "longName": "995200505 - Statement - Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_wKE5Vp0bX0GzjK5p_asUOQ", "name": "ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_adxn_AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember_ejVdiiB2p0aJQ9jSou7PZA", "name": "adxn:GainLossOnDiscontinuanceNetOfTaxNonCashItems", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R8": { "role": "http://addextherapeutics.com/role/DisclosureGeneralInformation", "longName": "995210101 - Disclosure - General information", "shortName": "General information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R9": { "role": "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPolicies", "longName": "995210201 - Disclosure - Summary of material accounting policies", "shortName": "Summary of material accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R10": { "role": "http://addextherapeutics.com/role/DisclosureFinancialRiskManagement", "longName": "995210301 - Disclosure - Financial risk management", "shortName": "Financial risk management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R11": { "role": "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgments", "longName": "995210401 - Disclosure - Material accounting estimates and judgments", "shortName": "Material accounting estimates and judgments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R12": { "role": "http://addextherapeutics.com/role/DisclosureSegmentInformation", "longName": "995210501 - Disclosure - Segment information", "shortName": "Segment information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R13": { "role": "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalents", "longName": "995210601 - Disclosure - Cash and cash equivalents", "shortName": "Cash and cash equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R14": { "role": "http://addextherapeutics.com/role/DisclosureOtherCurrentAssets", "longName": "995210701 - Disclosure - Other current assets", "shortName": "Other current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R15": { "role": "http://addextherapeutics.com/role/DisclosureRightOfUseAssets", "longName": "995210801 - Disclosure - Right-of-use assets", "shortName": "Right-of-use assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfRightOfUseAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfRightOfUseAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R16": { "role": "http://addextherapeutics.com/role/DisclosureEquipment", "longName": "995210901 - Disclosure - Equipment", "shortName": "Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R17": { "role": "http://addextherapeutics.com/role/DisclosureIntangibleAssets", "longName": "995211001 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R18": { "role": "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssets", "longName": "995211101 - Disclosure - Non-current financial assets", "shortName": "Non-current financial assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R19": { "role": "http://addextherapeutics.com/role/DisclosurePayablesAndAccruals", "longName": "995211201 - Disclosure - Payables and accruals", "shortName": "Payables and accruals", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R20": { "role": "http://addextherapeutics.com/role/DisclosureShareCapital", "longName": "995211301 - Disclosure - Share capital", "shortName": "Share capital", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R21": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensation", "longName": "995211401 - Disclosure - Share-based compensation", "shortName": "Share-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R22": { "role": "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomer", "longName": "995211501 - Disclosure - Revenue from contract with customer", "shortName": "Revenue from contract with customer", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R23": { "role": "http://addextherapeutics.com/role/DisclosureOtherIncome", "longName": "995211601 - Disclosure - Other income", "shortName": "Other income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R24": { "role": "http://addextherapeutics.com/role/DisclosureOperatingCosts", "longName": "995211701 - Disclosure - Operating costs", "shortName": "Operating costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R25": { "role": "http://addextherapeutics.com/role/DisclosureStaffCosts", "longName": "995211801 - Disclosure - Staff costs", "shortName": "Staff costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R26": { "role": "http://addextherapeutics.com/role/DisclosureTaxes", "longName": "995211901 - Disclosure - Taxes", "shortName": "Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R27": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligations", "longName": "995212001 - Disclosure - Retirement benefits obligations", "shortName": "Retirement benefits obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R28": { "role": "http://addextherapeutics.com/role/DisclosureFinanceResultNet", "longName": "995212101 - Disclosure - Finance result, net", "shortName": "Finance result, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R29": { "role": "http://addextherapeutics.com/role/DisclosureDiscontinuedOperations", "longName": "995212201 - Disclosure - Discontinued operations", "shortName": "Discontinued operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R30": { "role": "http://addextherapeutics.com/role/DisclosureInterestsInAssociates", "longName": "995212301 - Disclosure - Interests in associates", "shortName": "Interests in associates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R31": { "role": "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "longName": "995212401 - Disclosure - Financial assets at fair value through other comprehensive income", "shortName": "Financial assets at fair value through other comprehensive income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R32": { "role": "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstruments", "longName": "995212501 - Disclosure - Derivative financial instruments", "shortName": "Derivative financial instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R33": { "role": "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShare", "longName": "995212601 - Disclosure - Profit or loss per share", "shortName": "Profit or loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R34": { "role": "http://addextherapeutics.com/role/DisclosureCommitmentsAndContingencies", "longName": "995212701 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R35": { "role": "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactions", "longName": "995212801 - Disclosure - Related party transactions", "shortName": "Related party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R36": { "role": "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDate", "longName": "995212901 - Disclosure - Events after the balance sheet date", "shortName": "Events after the balance sheet date", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R37": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R38": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R39": { "role": "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of material accounting policies (Policies)", "shortName": "Summary of material accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R40": { "role": "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of material accounting policies (Tables)", "shortName": "Summary of material accounting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfDepreciationRatesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfDepreciationRatesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R41": { "role": "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementTables", "longName": "99930303 - Disclosure - Financial risk management (Tables)", "shortName": "Financial risk management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfNetDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfNetDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R42": { "role": "http://addextherapeutics.com/role/DisclosureSegmentInformationTables", "longName": "99930503 - Disclosure - Segment information (Tables)", "shortName": "Segment information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfProductsAndServicesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfProductsAndServicesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R43": { "role": "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsTables", "longName": "99930603 - Disclosure - Cash and cash equivalents (Tables)", "shortName": "Cash and cash equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R44": { "role": "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsTables", "longName": "99930703 - Disclosure - Other current assets (Tables)", "shortName": "Other current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfDetailedInformationAboutOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfDetailedInformationAboutOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R45": { "role": "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsTables", "longName": "99930803 - Disclosure - Right-of-use assets (Tables)", "shortName": "Right-of-use assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "adxn:DisclosureOfRightOfUseAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "adxn:DisclosureOfRightOfUseAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R46": { "role": "http://addextherapeutics.com/role/DisclosureEquipmentTables", "longName": "99930903 - Disclosure - Equipment (Tables)", "shortName": "Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R47": { "role": "http://addextherapeutics.com/role/DisclosureIntangibleAssetsTables", "longName": "99931003 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R48": { "role": "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsTables", "longName": "99931103 - Disclosure - Non-current financial assets (Tables)", "shortName": "Non-current financial assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R49": { "role": "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsTables", "longName": "99931203 - Disclosure - Payables and accruals (Tables)", "shortName": "Payables and accruals (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R50": { "role": "http://addextherapeutics.com/role/DisclosureShareCapitalTables", "longName": "99931303 - Disclosure - Share capital (Tables)", "shortName": "Share capital (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R51": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables", "longName": "99931403 - Disclosure - Share-based compensation (Tables)", "shortName": "Share-based compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R52": { "role": "http://addextherapeutics.com/role/DisclosureOperatingCostsTables", "longName": "99931703 - Disclosure - Operating costs (Tables)", "shortName": "Operating costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R53": { "role": "http://addextherapeutics.com/role/DisclosureStaffCostsTables", "longName": "99931803 - Disclosure - Staff costs (Tables)", "shortName": "Staff costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfStaffCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfStaffCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R54": { "role": "http://addextherapeutics.com/role/DisclosureTaxesTables", "longName": "99931903 - Disclosure - Taxes (Tables)", "shortName": "Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfReconciliationOfEffectiveTaxRateTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfReconciliationOfEffectiveTaxRateTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R55": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables", "longName": "99932003 - Disclosure - Retirement benefits obligations (Tables)", "shortName": "Retirement benefits obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfAmountsRecognizedInBalanceSheetForEmploymentBenefitObligationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfAmountsRecognizedInBalanceSheetForEmploymentBenefitObligationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R56": { "role": "http://addextherapeutics.com/role/DisclosureFinanceResultNetTables", "longName": "99932103 - Disclosure - Finance result, net (Tables)", "shortName": "Finance result, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfFinanceIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfFinanceIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R57": { "role": "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsTables", "longName": "99932203 - Disclosure - Discontinued operations (Tables)", "shortName": "Discontinued operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R58": { "role": "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesTables", "longName": "99932303 - Disclosure - Interests in associates (Tables)", "shortName": "Interests in associates (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R59": { "role": "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTables", "longName": "99932403 - Disclosure - Financial assets at fair value through other comprehensive income (Tables)", "shortName": "Financial assets at fair value through other comprehensive income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:TabularDisclosureOfInformationAboutFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:TabularDisclosureOfInformationAboutFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R60": { "role": "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsTables", "longName": "99932503 - Disclosure - Derivative financial instruments (Tables)", "shortName": "Derivative financial instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfFairValueMeasurementOfDerivativeFinancialInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:DisclosureOfFairValueMeasurementOfDerivativeFinancialInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R61": { "role": "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareTables", "longName": "99932603 - Disclosure - Profit or loss per share (Tables)", "shortName": "Profit or loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "61", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R62": { "role": "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsTables", "longName": "99932803 - Disclosure - Related party transactions (Tables)", "shortName": "Related party transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "62", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R63": { "role": "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "longName": "99940101 - Disclosure - General information (Details)", "shortName": "General information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_12_31_2025_To_12_31_2025_ifrs-full_SignificantInvestmentsInAssociatesAxis_adxn_NeurosterixUsHoldingsLlcMember_RZbmpJbg4UGOSwoGYU2VIg", "name": "ifrs-full:ProportionOfOwnershipInterestInAssociate", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R64": { "role": "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesConsolidationAndSegmentsDetails", "longName": "99940201 - Disclosure - Summary of material accounting policies - Consolidation and Segments (Details)", "shortName": "Summary of material accounting policies - Consolidation and Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:NumberOfSegments", "unitRef": "Unit_Standard_segment_9ANJyKDPMEuM5625iNt44Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPropertyPlantAndEquipmentDetails", "longName": "99940202 - Disclosure - Summary of material accounting policies - Property, plant and equipment (Details)", "shortName": "Summary of material accounting policies - Property, plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_V52HHck1h0eucsEd0r2i6A", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDepreciationRatesTableTextBlock", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_V52HHck1h0eucsEd0r2i6A", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDepreciationRatesTableTextBlock", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R66": { "role": "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesFinancialAssetsDetails", "longName": "99940203 - Disclosure - Summary of material accounting policies - Financial assets (Details)", "shortName": "Summary of material accounting policies - Financial assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_12_31_2025_To_12_31_2025_2-43q5AiTkGUTIqeXHRUtQ", "name": "adxn:NumberOfCategoriesOfFinancialAssets", "unitRef": "Unit_Standard_category_34bTBT6vbkSqwXGcZVrIPA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_12_31_2025_To_12_31_2025_2-43q5AiTkGUTIqeXHRUtQ", "name": "adxn:NumberOfCategoriesOfFinancialAssets", "unitRef": "Unit_Standard_category_34bTBT6vbkSqwXGcZVrIPA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R67": { "role": "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPensionObligationDetails", "longName": "99940204 - Disclosure - Summary of material accounting policies - Pension obligation (Details)", "shortName": "Summary of material accounting policies - Pension obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_12_31_2025_To_12_31_2025_2-43q5AiTkGUTIqeXHRUtQ", "name": "adxn:NumberOfPensionSchemes", "unitRef": "Unit_Standard_item_3pTL9THem0aHTIq8cZahyA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_12_31_2025_To_12_31_2025_2-43q5AiTkGUTIqeXHRUtQ", "name": "adxn:NumberOfPensionSchemes", "unitRef": "Unit_Standard_item_3pTL9THem0aHTIq8cZahyA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R68": { "role": "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails", "longName": "99940301 - Disclosure - Financial risk management (Details)", "shortName": "Financial risk management (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "adxn:InterestBearingDebt", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "adxn:InterestBearingDebt", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R69": { "role": "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails", "longName": "99940302 - Disclosure - Financial risk management - net debt (Details)", "shortName": "Financial risk management - net debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_12_31_2024_xpCHwOxz80-4HSTqnt3stw", "name": "ifrs-full:NetDebt", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "adxn:DisclosureOfNetDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_w_HQtbxtK0qHFiveaOsyMw", "name": "ifrs-full:NetDebt", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "adxn:DisclosureOfNetDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R70": { "role": "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementLeaseLiabilitiesDetails", "longName": "99940303 - Disclosure - Financial risk management - lease liabilities (Details)", "shortName": "Financial risk management - lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:GrossLeaseLiabilities", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "adxn:DisclosureOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:GrossLeaseLiabilities", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "adxn:DisclosureOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R71": { "role": "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "longName": "99940401 - Disclosure - Material accounting estimates and judgments - (Details)", "shortName": "Material accounting estimates and judgments - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:PercentageOfReasonablyPossibleIncreaseInVolatilityAssumption", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:PercentageOfReasonablyPossibleIncreaseInVolatilityAssumption", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R72": { "role": "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails", "longName": "99940501 - Disclosure - Segment information (Details)", "shortName": "Segment information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:NumberOfSegments", "unitRef": "Unit_Standard_segment_9ANJyKDPMEuM5625iNt44Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:RevenueFromCollaborativeResearchFunding", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfProductsAndServicesExplanatory", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R73": { "role": "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "longName": "99940601 - Disclosure - Cash and cash equivalents (Details)", "shortName": "Cash and cash equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:Cash", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:Cash", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R74": { "role": "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "longName": "99940701 - Disclosure - Other current assets (Details)", "shortName": "Other current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:OtherCurrentFinancialAssets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:OtherCurrentAssets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutOtherCurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R75": { "role": "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails", "longName": "99940801 - Disclosure - Right-of-use assets (Details)", "shortName": "Right-of-use assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "As_Of_12_31_2024_xpCHwOxz80-4HSTqnt3stw", "name": "ifrs-full:RightofuseAssets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_w_HQtbxtK0qHFiveaOsyMw", "name": "ifrs-full:RightofuseAssets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "adxn:DisclosureOfRightOfUseAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R76": { "role": "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "longName": "99940901 - Disclosure - Equipment (Details)", "shortName": "Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_12_31_2024_xpCHwOxz80-4HSTqnt3stw", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_w_HQtbxtK0qHFiveaOsyMw", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R77": { "role": "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "longName": "99941001 - Disclosure - Intangible assets (Details)", "shortName": "Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_wKE5Vp0bX0GzjK5p_asUOQ", "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_wKE5Vp0bX0GzjK5p_asUOQ", "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R78": { "role": "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsDetails", "longName": "99941101 - Disclosure - Non-current financial assets (Details)", "shortName": "Non-current financial assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:LongtermDeposits", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:LongtermDeposits", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R79": { "role": "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails", "longName": "99941201 - Disclosure - Payables and accruals (Details)", "shortName": "Payables and accruals (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R80": { "role": "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "longName": "99941301 - Disclosure - Share capital (Details)", "shortName": "Share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "As_Of_12_31_2024_xpCHwOxz80-4HSTqnt3stw", "name": "ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates", "unitRef": "Unit_Standard_shares_ZPBoKj2vD0GXMIx1Vktt4A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:NumberOfTreasurySharesSoldPurchased", "unitRef": "Unit_Standard_shares_ZPBoKj2vD0GXMIx1Vktt4A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R81": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails", "longName": "99941401 - Disclosure - Share-based compensation (Details)", "shortName": "Share-based compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_ifrs-full_DiscontinuedOperationsMember_TjbvnQBkHEKwf28IvjxsQg", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R82": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "longName": "99941402 - Disclosure - Share-based compensation - Share option plans - ESOP (Details)", "shortName": "Share-based compensation - Share option plans - ESOP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_EmployeeShareOptionPlansMember_OY8ZiT2fKUaHgJqeXSi2Mg", "name": "adxn:VestingPeriodOfOptionsGranted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_EmployeeShareOptionPlansMember_OY8ZiT2fKUaHgJqeXSi2Mg", "name": "adxn:VestingPeriodOfOptionsGranted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R83": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "longName": "99941403 - Disclosure - Share-based compensation - Share options outstanding - ESOP (Details)", "shortName": "Share-based compensation - Share options outstanding - ESOP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_EmployeeShareOptionPlansMember_rColKIUnzku4e_aRcTNvJQ", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Unit_Standard_Options_qAJB98r0tUKtYeVGRn7Dpw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_EmployeeShareOptionPlansMember_xqvo7ewS-0OYWeB6NJtjfw", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Unit_Standard_Options_qAJB98r0tUKtYeVGRn7Dpw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R84": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails", "longName": "99941404 - Disclosure - Share-based compensation - Share options plans assumptions - ESOP (Details)", "shortName": "Share-based compensation - Share options plans assumptions - ESOP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "As_Of_12_31_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_EmployeeShareOptionPlansMember_VFqMEacQOEq3ruDiZjVwQg", "name": "ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_EmployeeShareOptionPlansMember_VFqMEacQOEq3ruDiZjVwQg", "name": "ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R85": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails", "longName": "99941405 - Disclosure - Share-based compensation - Share option plans - DSPPP (Details)", "shortName": "Share-based compensation - Share option plans - DSPPP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_DeferredStrikePricePaymentPlanMember_BrCbl5dOK0W429dg3d8skQ", "name": "adxn:PaymentDeferralPeriodForEquityIncentiveUnitsExercised", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_DeferredStrikePricePaymentPlanMember_BrCbl5dOK0W429dg3d8skQ", "name": "adxn:PaymentDeferralPeriodForEquityIncentiveUnitsExercised", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R86": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "longName": "99941406 - Disclosure - Share-based compensation - Share options outstanding - DSPPP (Details)", "shortName": "Share-based compensation - Share options outstanding - DSPPP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_DeferredStrikePricePaymentPlanMember__CXOZPfLrUO0m7f4POA5LQ", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_EquityInstruments_Z2r9CqeEWkm2CHV2VTmOMg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_MaturityAxis_adxn_LaterThanSevenYearsAndNotLaterThanEightYearsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_DeferredStrikePricePaymentPlanMember_hMJoXT7LPUeReNU1klkrtg", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_EquityInstruments_Z2r9CqeEWkm2CHV2VTmOMg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R87": { "role": "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails", "longName": "99941501 - Disclosure - Revenue from contract with customer (Details)", "shortName": "Revenue from contract with customer (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_2_2018_To_1_2_2018_ifrs-full_CounterpartiesAxis_adxn_IndiviorPlcMember_qlq3E_vHeE6WNnGay7V8Qw", "name": "adxn:NumberOfDistinctMaterialPromisesAndPerformanceObligations", "unitRef": "Unit_Standard_item_3pTL9THem0aHTIq8cZahyA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R88": { "role": "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "longName": "99941601 - Disclosure - Other income (Details)", "shortName": "Other income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:OtherIncome", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_9_1_2023_To_9_30_2023_ifrs-full_CounterpartiesAxis_adxn_EurostarsInnosuisseMember_ifrs-full_ProductsAndServicesAxis_adxn_Mglu2NamProgramMember_7d5A9GlriEGPgx5t4adzZA", "name": "adxn:AmountOfGrantAwarded", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R89": { "role": "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails", "longName": "99941701 - Disclosure - Operating costs (Details)", "shortName": "Operating costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:InsuranceExpense", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R90": { "role": "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails", "longName": "99941702 - Disclosure - Operating costs - Additional Information (Details)", "shortName": "Operating costs - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:IncreaseDecreaseInOperatingExpenses", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:IncreaseDecreaseInOperatingExpenses", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R91": { "role": "http://addextherapeutics.com/role/DisclosureStaffCostsDetails", "longName": "99941801 - Disclosure - Staff costs (Details)", "shortName": "Staff costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:WagesAndSalaries", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfStaffCostsTableTextBlock", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:WagesAndSalaries", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfStaffCostsTableTextBlock", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R92": { "role": "http://addextherapeutics.com/role/DisclosureStaffCostsAdditionalInformationDetails", "longName": "99941802 - Disclosure - Staff costs - Additional Information (Details)", "shortName": "Staff costs - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R93": { "role": "http://addextherapeutics.com/role/DisclosureTaxesDetails", "longName": "99941901 - Disclosure - Taxes (Details)", "shortName": "Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "ifrs-full:DeferredTaxAssets", "ifrs-full:DeferredTaxAssets", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R94": { "role": "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails", "longName": "99941902 - Disclosure - Taxes - Tax loss (Details)", "shortName": "Taxes - Tax loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R95": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails", "longName": "99942001 - Disclosure - Retirement benefits obligations - Balance sheet (Details)", "shortName": "Retirement benefits obligations - Balance sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:PercentageOfContributionsByEmployee", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:PercentageOfContributionsByEmployee", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R96": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails", "longName": "99942002 - Disclosure - Retirement benefits obligations - Comprehensive loss (Details)", "shortName": "Retirement benefits obligations - Comprehensive loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfAmountsRecognizedInProfitOrLossForEmploymentBenefitObligationsTableTextBlock", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfAmountsRecognizedInProfitOrLossForEmploymentBenefitObligationsTableTextBlock", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R97": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails", "longName": "99942003 - Disclosure - Retirement benefit obligations - Movement (Details)", "shortName": "Retirement benefit obligations - Movement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "As_Of_12_31_2024_xpCHwOxz80-4HSTqnt3stw", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "adxn:DisclosureOfAmountsRecognizedInBalanceSheetForEmploymentBenefitObligationsTableTextBlock", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_ifrs-full_PresentValueOfDefinedBenefitObligationMember_gT63Wk7JS0eMBL5WAGQr4w", "name": "ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R98": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails", "longName": "99942004 - Disclosure - Retirement benefit obligations - Plan assets (Details)", "shortName": "Retirement benefit obligations - Plan assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "As_Of_12_31_2024_xpCHwOxz80-4HSTqnt3stw", "name": "ifrs-full:CashAndCashEquivalentsPercentageContributedToFairValueOfPlanAssets", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_xpCHwOxz80-4HSTqnt3stw", "name": "ifrs-full:CashAndCashEquivalentsPercentageContributedToFairValueOfPlanAssets", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R99": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails", "longName": "99942005 - Disclosure - Retirement benefit obligations - Assumptions (Details)", "shortName": "Retirement benefit obligations - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantActuarialAssumptionsUsedToDeterminePresentValueOfDefinedBenefitObligationExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantActuarialAssumptionsUsedToDeterminePresentValueOfDefinedBenefitObligationExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R100": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails", "longName": "99942006 - Disclosure - Retirement benefit obligations - Contributions and funding (Details)", "shortName": "Retirement benefit obligations - Contributions and funding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R101": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails", "longName": "99942007 - Disclosure - Retirement benefit obligations - Estimated benefit payments (Details)", "shortName": "Retirement benefit obligations - Estimated benefit payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_COI5orbtwEGkUKAjJxXX5A", "name": "adxn:EstimatedDefinedBenefitPayments", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfEstimatedBenefitPaymentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_COI5orbtwEGkUKAjJxXX5A", "name": "adxn:EstimatedDefinedBenefitPayments", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfEstimatedBenefitPaymentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R102": { "role": "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails", "longName": "99942101 - Disclosure - Finance result, net (Details)", "shortName": "Finance result, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_wKE5Vp0bX0GzjK5p_asUOQ", "name": "ifrs-full:RevenueFromInterest", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfFinanceIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_wKE5Vp0bX0GzjK5p_asUOQ", "name": "ifrs-full:RevenueFromInterest", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfFinanceIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R103": { "role": "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "longName": "99942201 - Disclosure - Discontinued operations - General (Details)", "shortName": "Discontinued operations - General (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "Duration_4_2_2024_To_4_2_2024_dei_LegalEntityAxis_adxn_NeurosterixPharmaSarlMember_WbHeM82et0aLt7OLsS4UPA", "name": "adxn:AmountOfCommitmentFundingReceived", "unitRef": "Unit_Standard_USD_roP9wYVuk0m_jWtfH5FFeQ", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_2_2024_To_4_2_2024_dei_LegalEntityAxis_adxn_NeurosterixPharmaSarlMember_WbHeM82et0aLt7OLsS4UPA", "name": "adxn:AmountOfCommitmentFundingReceived", "unitRef": "Unit_Standard_USD_roP9wYVuk0m_jWtfH5FFeQ", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R104": { "role": "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "longName": "99942202 - Disclosure - Discontinued operations - Financial performance of discontinued operations (Details)", "shortName": "Discontinued operations - Financial performance of discontinued operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:OtherIncome", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_adxn_AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember_ejVdiiB2p0aJQ9jSou7PZA", "name": "ifrs-full:OtherIncome", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R105": { "role": "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "longName": "99942203 - Disclosure - Discontinued operations - Operating costs of discontinued operations (Details)", "shortName": "Discontinued operations - Operating costs of discontinued operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_adxn_AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember_ejVdiiB2p0aJQ9jSou7PZA", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R106": { "role": "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "longName": "99942204 - Disclosure - Discontinued operations - Cash flow of discontinued operations (Details)", "shortName": "Discontinued operations - Cash flow of discontinued operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:ProfitLossFromDiscontinuedOperations", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_adxn_AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember_nIUQEjDiXU2P2YrLka04Rg", "name": "adxn:AdjustmentsForGainLossOnDiscontinuanceNetOfTax", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R107": { "role": "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "longName": "99942205 - Disclosure - Discontinued operations - Details of the net gain of the sale of activities (Details)", "shortName": "Discontinued operations - Details of the net gain of the sale of activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "Duration_4_2_2024_To_4_2_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_adxn_NeurosterixUsHoldingsLlcMember_w8Io_hGhxEuBYZXwpX0A5g", "name": "adxn:PercentageOfEquityInterestReceived", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_adxn_AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember_ejVdiiB2p0aJQ9jSou7PZA", "name": "adxn:NetGainOnDivestmentCompanyDerecognition", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R108": { "role": "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "longName": "99942301 - Disclosure - Interests in associates (Details)", "shortName": "Interests in associates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "As_Of_12_31_2024_xpCHwOxz80-4HSTqnt3stw", "name": "ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_adxn_NeurosterixGroupMember_ljB_x38-fkGsVbIwBdiUFw", "name": "adxn:IncreaseInInterestsInAssociates", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory", "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R109": { "role": "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails", "longName": "99942401 - Disclosure - Financial assets at fair value through other comprehensive income (Details)", "shortName": "Financial assets at fair value through other comprehensive income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_adxn_StaliclaSaMember_BUUgU_-9NkqvPpa-6Qxamw", "name": "ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R110": { "role": "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "longName": "99942501 - Disclosure - Derivative financial instruments (Details)", "shortName": "Derivative financial instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:NoncurrentDerivativeFinancialAssets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_gSOdxSX6SEWqzdZEizHRGQ", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R111": { "role": "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "longName": "99942502 - Disclosure - Derivative financial instruments - inputs (Details)", "shortName": "Derivative financial instruments - inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_ClassesOfFinancialInstrumentsAxis_ifrs-full_PreferenceSharesMember_GlZ_rpOwcEq8vwtGexB-Ag", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_ClassesOfFinancialInstrumentsAxis_ifrs-full_PreferenceSharesMember_ifrs-full_UnobservableInputsAxis_adxn_UnderlyingSharePriceMember_Pef7UTGV_Ea10aDEO3fYmw", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets", "unitRef": "Unit_Standard_pure_FR4kTQ6BBEmx1KFcdF6Wqw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets", "span", "div", "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } }, "R112": { "role": "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "longName": "99942601 - Disclosure - Profit or loss per share (Details)", "shortName": "Profit or loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R113": { "role": "http://addextherapeutics.com/role/DisclosureCommitmentsAndContingenciesCapitalCommitmentsAndContingenciesDetails", "longName": "99942701 - Disclosure - Commitments and contingencies - Capital commitments and contingencies (Details)", "shortName": "Commitments and contingencies - Capital commitments and contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "ifrs-full:ContractualCapitalCommitments", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OXIfocS37kGUS7VleeOWvg", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "ifrs-full:ContractualCapitalCommitments", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R114": { "role": "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99942801 - Disclosure - Related party transactions (Details)", "shortName": "Related party transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:KeyManagementPersonnelCompensationSalariesOtherShortTermEmployeeBenefitsAndPostEmploymentBenefits", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:KeyManagementPersonnelCompensationSalariesOtherShortTermEmployeeBenefitsAndPostEmploymentBenefits", "unitRef": "Unit_Standard_CHF_vi4EfuoCFkKtCS4tww2Zlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true, "unique": true } }, "R115": { "role": "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "longName": "99942901 - Disclosure - Events after the balance sheet date (Details)", "shortName": "Events after the balance sheet date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_i-zKZ2XdN02OWyNV8PUovw", "name": "adxn:SaleOfTreasuryShares", "unitRef": "Unit_Standard_shares_ZPBoKj2vD0GXMIx1Vktt4A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_4_29_2026_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_dB7IOtoYDUiX1uGR2R2PYg", "name": "adxn:ShareSalePrice", "unitRef": "Unit_Divide_CHF_shares_IDDvj3QWO0yBa5GB-fmW8Q", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20251231x20f.htm", "unique": true } } }, "tag": { "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r550" ] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation", "terseLabel": "Accumulated depreciation" } } }, "auth_ref": [ "r16", "r513", "r529", "r530", "r531" ] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated impairment" } } }, "auth_ref": [ "r161", "r174", "r297", "r376", "r513", "r529", "r530", "r531" ] }, "adxn_AchievementOfPreSpecifiedMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AchievementOfPreSpecifiedMilestonesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Achievement of pre-specified milestones [member]Achievement of pre-specified milestones", "label": "Achievement of pre-specified milestones", "terseLabel": "Achievement of pre-specified milestones" } } }, "auth_ref": [] }, "adxn_AcquisitionOfSharesForfeitedFromDeferredStrikePricePaymentPlan": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AcquisitionOfSharesForfeitedFromDeferredStrikePricePaymentPlan", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Acquisition of shares forfeited from Deferred Strike Price Payment Plan (DSPPP).", "label": "Acquisition Of Shares Forfeited From Deferred Strike Price Payment Plan", "negatedLabel": "Acquisition of shares forfeited from DSPPP" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of discount rates", "terseLabel": "Discount rate" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r523" ] }, "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRatesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate", "terseLabel": "Discount rate" } }, "en": { "role": { "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r524" ] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfPensionIncreases", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of expected rates of pension increases", "terseLabel": "Pension growth rate" } }, "en": { "role": { "documentation": "The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [domain]; Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r523" ] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of expected rates of salary increases", "terseLabel": "Salary growth rate" } }, "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [domain]; Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r523" ] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Salaries", "terseLabel": "Salaries" } }, "en": { "role": { "documentation": "This member stands for the expected rates of salary increases used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r524" ] }, "adxn_ActuarialAssumptionOfInterestRatesOnRetirementSavingsCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ActuarialAssumptionOfInterestRatesOnRetirementSavingsCapitalMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Actuarial assumption of interest rates on retirement savings capital", "label": "Interest rates on retirement savings capital", "terseLabel": "Interest rates on retirement savings capital" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfLifeExpectancyAfterRetirementMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Life expectancy", "terseLabel": "Life expectancy" } }, "en": { "role": { "documentation": "This member stands for the life expectancy after retirement used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r524" ] }, "ifrs-full_ActuarialAssumptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumptions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r32" ] }, "ifrs-full_ActuarialAssumptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumptions [domain]" } }, "en": { "role": { "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used." } } }, "auth_ref": [ "r32" ] }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)", "terseLabel": "Actuarial (loss)/ gain arising from changes in financial assumptions" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r25" ] }, "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial gains (losses) arising from experience adjustments, net defined benefit liability (asset)", "terseLabel": "Actuarial gain on experience adjustment" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r516" ] }, "adxn_ActuarialGainsLossesNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ActuarialGainsLossesNetDefinedBenefitLiabilityAsset", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails": { "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails" ], "lang": { "en-us": { "role": { "documentation": "Actuarial gains (losses), net defined benefit liability (asset)", "label": "Actuarial gains (losses), net defined benefit liability (asset)", "terseLabel": "Actuarial (loss)/ gain on defined benefit obligation" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r449" ] }, "adxn_AdditionalFundingForResearchAndDevelopmentCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AdditionalFundingForResearchAndDevelopmentCostsIncurred", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional funding for research and development costs incurred", "label": "Additional funding for research and development costs incurred", "terseLabel": "Additional funding for research and development costs incurred" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "terseLabel": "Additions" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r69", "r271" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment", "terseLabel": "Additions" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r11", "r239" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r462" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r462" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r462" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r462" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Weighed average number of shares in issue - diluted" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r59" ] }, "adxn_AdjustmentsForCostOfFairValueOfServicesReceivedAtZeroCost": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AdjustmentsForCostOfFairValueOfServicesReceivedAtZeroCost", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for cost of fair value of services received at zero cost", "label": "Adjustments for cost of fair value of services received at zero cost", "terseLabel": "Fair value of services received at zero cost recorded as other operating costs" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInContractAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments For Decrease Increase In Contract Assets", "terseLabel": "Decrease in contract asset" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in contract assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract assets; Profit (loss)]" } } }, "auth_ref": [ "r534" ] }, "adxn_AdjustmentsForDecreaseIncreaseInMiscellaneousOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AdjustmentsForDecreaseIncreaseInMiscellaneousOtherCurrentAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 4.0 }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in miscellaneous other current assets", "label": "Adjustments for decrease (increase) in miscellaneous other current assets", "terseLabel": "Decrease / (increase) in other current assets", "verboseLabel": "Increase in other current assets" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInOtherFinancialAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in other financial assets", "verboseLabel": "Decrease / (increase) in other financial assets" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in financial assets that the entity does not separately disclose in the same statement or note to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other financial assets; Profit (loss)]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepayments", "terseLabel": "Decrease / (increase) in prepayments", "verboseLabel": "Decrease / (increase) in prepayments" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Decrease in trade and other receivables", "verboseLabel": "Decrease / (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_AdjustmentsForDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for depreciation expense", "terseLabel": "Depreciation" } }, "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceIncomeCost", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": -1.0, "order": 7.0 }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for finance income (cost)", "negatedLabel": "Finance cost / (income) net", "negatedTerseLabel": "Finance cost net" } } }, "auth_ref": [ "r536" ] }, "adxn_AdjustmentsForGainLossOnDiscontinuanceNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AdjustmentsForGainLossOnDiscontinuanceNetOfTax", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 11.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for gain (loss), net of tax on discontinuance when operations are discontinued to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Gain (Loss) On Discontinuance, Net Of Tax", "negatedLabel": "Net gain on Neurosterix Transaction" } } }, "auth_ref": [] }, "adxn_AdjustmentsForGainLossRelatedToLeaseModification": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AdjustmentsForGainLossRelatedToLeaseModification", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": -1.0, "order": 8.0 }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for gain (loss) related to lease modification to net cash flow from (used in) operating activities.", "label": "Adjustments for Gain (Loss) Related to Lease Modification", "negatedLabel": "Net gain related to lease modification" } } }, "auth_ref": [] }, "adxn_AdjustmentsForIncomeOfFairValueOfServicesReceivedAtZeroCost": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AdjustmentsForIncomeOfFairValueOfServicesReceivedAtZeroCost", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for income of fair value of services received at zero cost", "label": "Adjustments for income of fair value of services received at zero cost", "negatedLabel": "Fair value of services received at zero cost recorded as income" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in deferred income", "terseLabel": "Decrease in deferred income", "verboseLabel": "Increase / (decrease) in deferred income" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in deferred income other than contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income other than contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r534" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 3.0 }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "terseLabel": "Increase / (decrease) in payables and accruals", "verboseLabel": "Increase / (decrease) in payables and accruals" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_AdjustmentsForProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForProvisions", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for provisions", "verboseLabel": "Post-employment benefits" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Adjustments for:" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 9.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Value of share-based services" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUndistributedProfitsOfAssociates", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for undistributed profits of associates", "negatedLabel": "Share of the net loss of associates" } } }, "auth_ref": [ "r535" ] }, "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AdrMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "American Depositary Shares", "terseLabel": "ADS", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": [ "r402" ] }, "adxn_AdsSalePrice": { "xbrltype": "perShareItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AdsSalePrice", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "documentation": "ADS sale price", "label": "ADS sale price" } } }, "auth_ref": [] }, "ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AggregateContinuingAndDiscontinuedOperationsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate continuing and discontinued operations [member]", "terseLabel": "Continuing and discontinued operations" } }, "en": { "role": { "documentation": "This member stands for the aggregate of continuing and discontinued operations. [Refer: Discontinued operations [member]; Continuing operations, unless line item indicates otherwise [member]]" } } }, "auth_ref": [ "r168" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r507" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r420", "r431", "r441", "r474" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r423", "r434", "r444", "r477" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r508" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r462" ] }, "adxn_AllAssetsPercentageContributedToFairValueOfPlanAssets": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AllAssetsPercentageContributedToFairValueOfPlanAssets", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "All assets, percentage contributed to fair value of plan assets", "label": "All assets, percentage contributed to fair value of plan assets", "totalLabel": "Total" } } }, "auth_ref": [] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r469" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r424", "r435", "r445", "r469", "r478", "r482", "r490" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r488" ] }, "adxn_AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "This member stands for allosteric modulator drug discovery technology platform and a portfolio of preclinical programs constituting as discontinued operations.", "label": "Allosteric Modulator Drug Discovery Technology Platform And A Portfolio Of Preclinical Programs, Disposal Group, Discontinued Operations [Member]", "terseLabel": "Discontinued operations as disclosed below" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Amortisation, intangible assets other than goodwill", "negatedLabel": "Depreciation charge" } } }, "auth_ref": [ "r70", "r272" ] }, "adxn_AmountNotRecordedAsPhantomSharesDueToCapOnFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AmountNotRecordedAsPhantomSharesDueToCapOnFairValue", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount not recorded as phantom shares due to cap on fair value", "label": "Amount not recorded as phantom shares due to cap on fair value" } } }, "auth_ref": [] }, "adxn_AmountOfCommitmentFundingReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AmountOfCommitmentFundingReceived", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from committed funding.", "label": "Amount of Commitment Funding Received", "terseLabel": "Amount of committed funding received in million" } } }, "auth_ref": [] }, "adxn_AmountOfEquityInterestReceivedOnDisposalOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AmountOfEquityInterestReceivedOnDisposalOfDiscontinuedOperation", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsConsideration", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Amount of equity interest received on disposal of discontinued operation", "label": "Amount of equity interest received on disposal of discontinued operation", "terseLabel": "Fair value of Neurosterix US Holdings LLC's participation" } } }, "auth_ref": [] }, "adxn_AmountOfGrantAwarded": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AmountOfGrantAwarded", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of grant awarded", "label": "Amount of grant awarded", "terseLabel": "Amount of grant awarded" } } }, "auth_ref": [] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Amounts payable, related party transactions", "terseLabel": "Net payable" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r43", "r46", "r261" ] }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsReceivableRelatedPartyTransactions", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Amounts receivable, related party transactions", "terseLabel": "Net receivable" } }, "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r43", "r46", "r261" ] }, "adxn_AntiDilutionProtectionMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "AntiDilutionProtectionMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Anti-dilution protection", "label": "Anti-dilution protection" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Applicable tax rate", "terseLabel": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r4", "r233" ] }, "ifrs-full_AssetbackedSecuritiesPercentageContributedToFairValueOfPlanAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetbackedSecuritiesPercentageContributedToFairValueOfPlanAssets", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails": { "parentTag": "adxn_AllAssetsPercentageContributedToFairValueOfPlanAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Mortgages, percentage contributed to fair value of plan assets", "terseLabel": "Mortgages" } }, "en": { "role": { "documentation": "The percentage securities that are backed by underlying assets contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [domain]] [Contrast: Asset-backed securities, amount contributed to fair value of plan assets]" } } }, "auth_ref": [ "r522" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r112", "r113", "r115", "r189", "r192", "r302", "r303", "r332" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "ifrs-full_AssetsAndLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAndLiabilitiesAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Assets and liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r39", "r229", "r258", "r311", "r322" ] }, "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Assets and liabilities classified as held for sale [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r167" ] }, "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAndLiabilitiesClassifiedAsHeldForSaleMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Assets and liabilities classified as held for sale [member]", "terseLabel": "Assets and liabilities held for sale" } }, "en": { "role": { "documentation": "This member stands for assets and liabilities that are classified as held for sale. [Refer: Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]" } } }, "auth_ref": [ "r167" ] }, "ifrs-full_AssetsAndLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAndLiabilitiesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Assets and liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for assets and liabilities. It also represents the standard value for the 'Assets and liabilities' axis if no other member is used. [Refer: Assets; Liabilities]" } } }, "auth_ref": [ "r39", "r229", "r258", "r311", "r322" ] }, "ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Assets and liabilities not classified as held for sale [member]" } }, "en": { "role": { "documentation": "This member stands for assets and liabilities that are not classified as held for sale. It also represents the standard value for the 'Assets and liabilities classified as held for sale' axis if no other member is used. [Refer: Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]" } } }, "auth_ref": [ "r167" ] }, "ifrs-full_AtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AtFairValueMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "At fair value [member]", "terseLabel": "Measured at fair value" } }, "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } } }, "auth_ref": [ "r75", "r79", "r97", "r112", "r279", "r301", "r302" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r545", "r547" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r545", "r547" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r403", "r404", "r427" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r403", "r404", "r427" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r403", "r404", "r427" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r485" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r486" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r481" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r481" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r481" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r481" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r481" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r481" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r484" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r483" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r482" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r482" ] }, "adxn_BalanceSheetLocationMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "BalanceSheetLocationMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Balance sheet location", "label": "Balance sheet location [Member]" } } }, "auth_ref": [] }, "ifrs-full_BalancesWithBanks": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BalancesWithBanks", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Balances with banks", "terseLabel": "Balances with banks" } }, "en": { "role": { "documentation": "The amount of cash balances held at banks." } } }, "auth_ref": [ "r537" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "totalLabel": "Basic profit / (loss) per share for profit/(loss) attributable to the ordinary equity holders of the Company" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r55", "r56" ] }, "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShareFromContinuingOperations", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_BasicEarningsLossPerShare", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share from continuing operations", "terseLabel": "From continuing operations" } }, "en": { "role": { "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]" } } }, "auth_ref": [ "r55", "r56" ] }, "ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShareFromDiscontinuedOperations", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_BasicEarningsLossPerShare", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share from discontinued operations", "terseLabel": "From discontinued operations" } }, "en": { "role": { "documentation": "Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]" } } }, "auth_ref": [ "r56", "r57" ] }, "ifrs-full_BasicEarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsPerShareAbstract", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Basic earnings per share [abstract]", "terseLabel": "Basic profit / (loss) per share" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r85", "r118", "r139", "r154", "r223", "r369", "r370", "r543" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r404", "r427" ] }, "country_CH": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "CH", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "SWITZERLAND", "terseLabel": "Switzerland" } } }, "auth_ref": [] }, "currency_CHF": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "CHF", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "CHF" } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r10", "r13", "r68", "r71", "r76", "r77", "r78", "r79", "r80", "r161", "r174", "r175", "r238", "r241", "r270", "r273", "r276", "r277", "r278", "r279", "r280", "r292", "r297", "r298" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } } }, "auth_ref": [ "r13", "r71", "r76", "r78", "r79", "r161", "r174", "r175", "r241", "r273", "r276", "r278", "r279", "r292", "r297", "r298" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash at bank and on hand" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r537" ] }, "adxn_CashAndCashEquivalentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CashAndCashEquivalentLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents", "label": "Cash and cash equivalent [Line Items]", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "adxn_CashAndCashEquivalentMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CashAndCashEquivalentMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents", "label": "Cash and cash equivalents [member]", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents.", "periodEndLabel": "Cash and cash equivalents at end of the year", "periodStartLabel": "Cash and cash equivalents at beginning of the year", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r86", "r107", "r224", "r329" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalentsPercentageContributedToFairValueOfPlanAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsPercentageContributedToFairValueOfPlanAssets", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails": { "parentTag": "adxn_AllAssetsPercentageContributedToFairValueOfPlanAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents, percentage contributed to fair value of plan assets", "terseLabel": "Cash" } }, "en": { "role": { "documentation": "The percentage cash and cash equivalents contribute to the fair value of defined benefit plan assets. [Refer: Cash and cash equivalents; Plan assets, at fair value; Defined benefit plans [domain]] [Contrast: Cash and cash equivalents, amount contributed to fair value of plan assets]" } } }, "auth_ref": [ "r517" ] }, "adxn_CashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CashAndCashEquivalentsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents", "label": "Cash and cash equivalents [Table]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash from financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r81", "r88" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows from financing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities, discontinued operations", "totalLabel": "Net cash used in financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]" } } }, "auth_ref": [ "r166" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash from/(used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r81", "r88" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows from / (used in) investing activities", "verboseLabel": "Net cash flow from / (used in) investing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities, discontinued operations", "totalLabel": "Net cash from / (used) in investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]" } } }, "auth_ref": [ "r166" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "auth_ref": [ "r81", "r88" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities, discontinued operations", "totalLabel": "Net cash flow used in operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]" } } }, "auth_ref": [ "r166" ] }, "ifrs-full_CashOnHand": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashOnHand", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash on hand", "terseLabel": "Cash on hand" } }, "en": { "role": { "documentation": "The amount of cash held by the entity. This does not include demand deposits." } } }, "auth_ref": [ "r537" ] }, "ifrs-full_CashOutflowForLeases": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashOutflowForLeases", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Cash outflow for leases" } }, "en": { "role": { "documentation": "The cash outflow for leases." } } }, "auth_ref": [ "r131", "r206" ] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r182", "r295" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r182", "r295" ] }, "ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfNoncurrentFinancialAssetsAbstract", "lang": { "en-us": { "role": { "label": "Non-current financial assets" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r45", "r263" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r45", "r263" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r460" ] }, "adxn_ChemicalLibraryMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ChemicalLibraryMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for chemical library.", "label": "Chemical library", "terseLabel": "Chemical library" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r457" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r455" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r61", "r63", "r117", "r133", "r208", "r266", "r304" ] }, "ifrs-full_ClassesOfAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r61", "r117", "r133", "r208", "r266", "r304" ] }, "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfEmployeeBenefitsExpenseAbstract", "lang": { "en-us": { "role": { "label": "Staff costs" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r174", "r176", "r177", "r178", "r297", "r299" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r174", "r176", "r177", "r178", "r297", "r299" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r72", "r274" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r72", "r274" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r14", "r242" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r14", "r242" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r221", "r308", "r344" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r221", "r308", "r344" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r461" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r461" ] }, "adxn_CommitmentsAndContingenciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CommitmentsAndContingenciesAbstract", "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies", "label": "Commitments and contingencies" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r466" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r465" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r467" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r464" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r320" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r320" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]", "verboseLabel": "Items that may be classified subsequently to profit or loss:" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]", "verboseLabel": "Items that will never be reclassified to profit and loss:" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureConsolidatedStatementsOfComprehensiveProfitOrLossCalc2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive profit / (loss) for the period", "verboseLabel": "Total comprehensive loss" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r92", "r94", "r102", "r265", "r282", "r316", "r348", "r368" ] }, "ifrs-full_ComprehensiveIncomeFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeFromContinuingOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureConsolidatedStatementsOfComprehensiveProfitOrLossCalc2": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income from continuing operations", "terseLabel": "From continuing operations" } }, "en": { "role": { "documentation": "The comprehensive income from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Comprehensive income]" } } }, "auth_ref": [ "r542" ] }, "ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeFromDiscontinuedOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureConsolidatedStatementsOfComprehensiveProfitOrLossCalc2": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income from discontinued operations", "terseLabel": "From discontinued operations" } }, "en": { "role": { "documentation": "The comprehensive income from discontinued operations. [Refer: Discontinued operations [member]; Comprehensive income]" } } }, "auth_ref": [ "r542" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer equipment", "terseLabel": "Computer equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r512" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_ContinuingAndDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContinuingAndDiscontinuedOperationsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureTaxesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Continuing and discontinued operations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r168" ] }, "ifrs-full_ContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContinuingOperationsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureTaxesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Continuing operations [member]" } }, "en": { "role": { "documentation": "This member stands for components of the entity that are not discontinued operations. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. This meaning may be overridden for line items which are either intrinsically related to discontinued operations (or disposal groups held for sale), or which are typically reported for the aggregate of continuing and discontinued. This member also represents the standard value for the 'Continuing and discontinued operations' axis if no other member is used. [Refer: Discontinued operations [member]; Aggregate continuing and discontinued operations [member]]" } } }, "auth_ref": [ "r168" ] }, "adxn_ContractAssetsAndTradeAndOtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ContractAssetsAndTradeAndOtherReceivablesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Contract assets and trade and other receivables", "label": "Trade and other receivables", "terseLabel": "Contract assets and trade and other receivables" } } }, "auth_ref": [] }, "adxn_ContractFundingForResearchAndDevelopmentCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ContractFundingForResearchAndDevelopmentCostsIncurred", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Contract funding for research and development costs incurred", "label": "Contract funding for research and development costs incurred" } } }, "auth_ref": [] }, "ifrs-full_ContractualCapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractualCapitalCommitments", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureCommitmentsAndContingenciesCapitalCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Contractual capital commitments", "terseLabel": "Contracted capital expenditure" } }, "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } } }, "auth_ref": [ "r547" ] }, "ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails" ], "lang": { "en-us": { "role": { "label": "Contributions to plan by employer, net defined benefit liability (asset)", "terseLabel": "Employer contributions" } }, "en": { "role": { "documentation": "The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [domain]]" } } }, "auth_ref": [ "r27" ] }, "ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails" ], "lang": { "en-us": { "role": { "label": "Contributions to plan by plan participants, net defined benefit liability (asset)", "terseLabel": "Employee contributions" } }, "en": { "role": { "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [domain]]" } } }, "auth_ref": [ "r27" ] }, "adxn_CostOfAcceleratedVestingOfEquityIncentiveUnitsOfEmployeesTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CostOfAcceleratedVestingOfEquityIncentiveUnitsOfEmployeesTransferred", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Cost of accelerated vesting of equity incentive units of employees transferred", "label": "Cost of accelerated vesting of equity incentive units of employees transferred", "negatedLabel": "Accelerating vesting ESOP/DSPPP", "terseLabel": "Accelerated vesting of equity incentive units of employees and Executive Managers transferred to Neurosterix Pharma Sarl" } } }, "auth_ref": [] }, "adxn_CostOfLegalFeesForDisposalOfDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CostOfLegalFeesForDisposalOfDiscontinuedOperations", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Cost of legal fees for disposal of discontinued operations", "label": "Cost of legal fees for disposal of discontinued operations", "negatedLabel": "Legal fees paid for Neurosterix Transaction" } } }, "auth_ref": [] }, "adxn_CostOfPreFundedWarrantsExercisedEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CostOfPreFundedWarrantsExercisedEquity", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Cost of pre-funded warrants exercised, equity", "label": "Cost of pre-funded warrants exercised, equity", "negatedLabel": "Costs of pre-funded warrants exercised" } } }, "auth_ref": [] }, "adxn_CostOfSaleOfPreFundedWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CostOfSaleOfPreFundedWarrantsEquity", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Cost of sale of pre-funded warrants", "label": "Cost of sale of pre-funded warrants, equity", "negatedLabel": "Cost of pre-funded warrants sold" } } }, "auth_ref": [] }, "adxn_CostOfSaleOfTreasurySharesEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CostOfSaleOfTreasurySharesEquity", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of costs on sale of treasury shares.", "label": "Cost of sale of treasury shares, equity", "negatedTerseLabel": "Costs related to the sale of treasury shares" } } }, "auth_ref": [] }, "adxn_CostOfSalesAgencyAgreementTransactionsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CostOfSalesAgencyAgreementTransactionsEquity", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Cost of sales agency agreement transactions, equity", "label": "Cost of sales agency agreement transactions, equity", "negatedLabel": "Costs under sale agency agreement" } } }, "auth_ref": [] }, "adxn_CostsPaidOnIssueOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CostsPaidOnIssueOfTreasuryShares", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Costs paid on issue of treasury shares", "label": "Costs paid on issue of treasury shares", "negatedLabel": "Cost of treasury share issuance" } } }, "auth_ref": [] }, "adxn_CostsPaidOnSaleOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CostsPaidOnSaleOfTreasuryShares", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Costs paid on sale of treasury shares", "label": "Costs paid on sale of treasury shares", "negatedLabel": "Cost paid on sale of treasury shares" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r183" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "adxn_CriticalAccountingEstimatesAndJudgmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "CriticalAccountingEstimatesAndJudgmentsAbstract", "lang": { "en-us": { "role": { "documentation": "Material accounting estimates and judgments", "label": "Material accounting estimates and judgments" } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange risk", "terseLabel": "Foreign exchange risk" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r140", "r141", "r142", "r143", "r184" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets", "terseLabel": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r98", "r336", "r368" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Current borrowings and current portion of non-current borrowings", "terseLabel": "Short-term debt" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r549" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r127" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "terseLabel": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r100", "r337", "r368" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Current payables on social security and taxes other than income tax", "terseLabel": "Social security and other taxes" } }, "en": { "role": { "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } } }, "auth_ref": [ "r550" ] }, "ifrs-full_CurrentPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepayments", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current prepayments", "terseLabel": "Prepayments" } }, "en": { "role": { "documentation": "The amount of current prepayments. [Refer: Prepayments]" } } }, "auth_ref": [ "r389", "r395" ] }, "ifrs-full_CurrentServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Current service cost on defined benefit plans", "negatedLabel": "Current service cost" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails" ], "lang": { "en-us": { "role": { "label": "Current service cost, net defined benefit liability (asset)", "negatedTerseLabel": "Current service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r22", "r247" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r412", "r501" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r412", "r501" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r414", "r503" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r414", "r503" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r416", "r505" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r414", "r503" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r407", "r496" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r408", "r497" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r408", "r497" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r406", "r495" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r406", "r495" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r406", "r495" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r409", "r498" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r411", "r500" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r411", "r500" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r412", "r501" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r415", "r504" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r413", "r502" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r410", "r499" ] }, "adxn_DateOfGrantAxis": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DateOfGrantAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Date of grant", "label": "Date of grant [axis]" } } }, "auth_ref": [] }, "adxn_DateOfGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DateOfGrantMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Date of grant", "label": "Date of grant [member]" } } }, "auth_ref": [] }, "ifrs-full_DebtInstrumentsPercentageContributedToFairValueOfPlanAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DebtInstrumentsPercentageContributedToFairValueOfPlanAssets", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails": { "parentTag": "adxn_AllAssetsPercentageContributedToFairValueOfPlanAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Bonds, percentage contributed to fair value of plan assets", "terseLabel": "Bonds" } }, "en": { "role": { "documentation": "The percentage instruments representing debt (rather than equity) contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [domain]] [Contrast: Debt instruments, amount contributed to fair value of plan assets]" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_DeferredIncomeOtherThanContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredIncomeOtherThanContractLiabilities", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred income.", "terseLabel": "Deferred income" } }, "en": { "role": { "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, other than contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r549", "r550" ] }, "adxn_DeferredStrikePricePaymentPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DeferredStrikePricePaymentPlanMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "documentation": "Deferred Strike Price Payment Plan", "label": "Deferred Strike Price Payment Plan (DSPPP)" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred income tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r6", "r235", "r331", "r333" ] }, "adxn_DefinedBenefitPlanContributionsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DefinedBenefitPlanContributionsPaid", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for defined benefit plan contributions paid.", "label": "Defined Benefit Plan, Contributions Paid", "terseLabel": "Paid pension contributions related to continuing activities" } } }, "auth_ref": [] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "terseLabel": "Depreciation (notes 8/9)", "verboseLabel": "Depreciation" } } }, "auth_ref": [ "r547" ] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "negatedLabel": "Depreciation charge" } } }, "auth_ref": [ "r12", "r15", "r240" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, right-of-use assets", "negatedTerseLabel": "Depreciation charge" } } }, "auth_ref": [ "r128", "r203" ] }, "ifrs-full_DerivativesPercentageContributedToFairValueOfPlanAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativesPercentageContributedToFairValueOfPlanAssets", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails": { "parentTag": "adxn_AllAssetsPercentageContributedToFairValueOfPlanAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Derivatives, percentage contributed to fair value of plan assets", "terseLabel": "Derivatives" } }, "en": { "role": { "documentation": "The percentage derivatives contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [domain]] [Contrast: Derivatives, amount contributed to fair value of plan assets]" } } }, "auth_ref": [ "r521" ] }, "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for deferred income tax [text block]", "terseLabel": "Deferred income tax" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Pension obligations" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r548" ] }, "adxn_DescriptionOfAccountingPolicyForEquityInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DescriptionOfAccountingPolicyForEquityInstrumentsTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for equity instruments", "label": "Description of accounting policy for equity instruments [text block]", "terseLabel": "Equity instruments" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for finance income and costs [text block]", "terseLabel": "Finance income and expense" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for financial assets [text block]", "terseLabel": "Financial assets" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Foreign currency transactions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for government grants [text block]", "terseLabel": "Grants" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r36", "r255" ] }, "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for investment in associates and joint ventures [text block]", "terseLabel": "Equity method" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Total for all associates [member]; Total for all joint ventures [member]]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for issued capital [text block]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Leases" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenue recognition" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for research and development expense [text block]", "terseLabel": "Research and development" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Segment reporting" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based compensation" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for trade and other payables [text block]", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r87", "r225" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]", "terseLabel": "New standards and interpretations not yet adopted by the Group" } } }, "auth_ref": [ "r90", "r228" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Weighted average volatility" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r156" ] }, "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of initial application of standards or interpretations [text block]", "terseLabel": "New and amended standards adopted by the Group" } } }, "auth_ref": [ "r89", "r227" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails" ], "lang": { "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Weighted average expected option life (years)" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r156" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Weighted average annual risk-free rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r156" ] }, "adxn_DevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DevelopmentMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Development", "label": "Development", "terseLabel": "Development" } } }, "auth_ref": [] }, "adxn_DifferenceBetweenCarryingAmountOfEquityAccountedInvestmentAndShareOfNetAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DifferenceBetweenCarryingAmountOfEquityAccountedInvestmentAndShareOfNetAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails" ], "lang": { "en-us": { "role": { "documentation": "Difference between carrying amount of equity-accounted investment and share of net assets", "label": "Difference between carrying amount of equity-accounted investment and share of net assets" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "totalLabel": "Diluted profit / (loss) per share for profit/ (loss) attributable to the ordinary equity holders of the Company" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r55", "r56" ] }, "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShareFromContinuingOperations", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_DilutedEarningsLossPerShare", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share from continuing operations", "terseLabel": "From continuing operations" } }, "en": { "role": { "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]" } } }, "auth_ref": [ "r55", "r56" ] }, "ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShareFromDiscontinuedOperations", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_DilutedEarningsLossPerShare", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share from discontinued operations", "terseLabel": "From discontinued operations" } }, "en": { "role": { "documentation": "Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]" } } }, "auth_ref": [ "r56", "r57" ] }, "ifrs-full_DilutedEarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsPerShareAbstract", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Diluted earnings per share [abstract]", "terseLabel": "Diluted profit / (loss) per share" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgments" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Material accounting estimates and judgments" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r544" ] }, "adxn_DisclosureOfAmountsRecognizedInBalanceSheetForEmploymentBenefitObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfAmountsRecognizedInBalanceSheetForEmploymentBenefitObligationsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of amounts recognized in balance sheet for employment benefit obligations", "label": "Disclosure of amounts recognized in balance sheet for employment benefit obligations [Table Text Block]", "terseLabel": "Schedule of amounts recognized in balance sheet for employment benefit obligations" } } }, "auth_ref": [] }, "adxn_DisclosureOfAmountsRecognizedInProfitOrLossForEmploymentBenefitObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfAmountsRecognizedInProfitOrLossForEmploymentBenefitObligationsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of amounts recognized in profit or loss for employment benefit obligations", "label": "Disclosure of amounts recognized in profit or loss for employment benefit obligations [Table Text Block]", "terseLabel": "Schedule of amounts recognized in statement of profit or loss for employment benefit obligations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of analysis of single amount of discontinued operations [text block]", "terseLabel": "Schedule of discontinued operations" } }, "en": { "role": { "documentation": "The disclosure of the analysis of the single amount of discontinued operations. [Refer: Discontinued operations [member]]" } } }, "auth_ref": [ "r165" ] }, "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Disclosure of analysis of single amount of discontinued operations [line items]", "terseLabel": "Disclosure" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Disclosure of analysis of single amount of discontinued operations [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the analysis of the single amount of discontinued operations." } } }, "auth_ref": [ "r165" ] }, "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfConsolidationExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of basis of consolidation [text block]", "terseLabel": "Consolidation" } }, "en": { "role": { "documentation": "The disclosure of the basis used for consolidation." } } }, "auth_ref": [ "r544" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of preparation" } } }, "auth_ref": [ "r544" ] }, "adxn_DisclosureOfCashAndCashEquivalentsByCreditRatingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfCashAndCashEquivalentsByCreditRatingTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash and cash equivalents by credit rating", "label": "Disclosure of cash and cash equivalents by credit rating [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents by credit rating" } } }, "auth_ref": [] }, "adxn_DisclosureOfCashAndCashEquivalentsByCurrencyTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfCashAndCashEquivalentsByCurrencyTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash and cash equivalents by currency", "label": "Disclosure of cash and cash equivalents by currency [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents by currency" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalents" ], "lang": { "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Share capital." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of share capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r221", "r308", "r344" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r221", "r308", "r344" ] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block]", "terseLabel": "Commitments and contingencies" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "label": "Retirement benefits obligations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligations" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [text block]", "terseLabel": "Retirement benefits obligations" } }, "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r18", "r243" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [line items]", "terseLabel": "Defined benefit plans" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r18", "r243" ] }, "adxn_DisclosureOfDepreciationRatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfDepreciationRatesTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of depreciation rates", "label": "Disclosure of depreciation rates [Table Text Block]", "terseLabel": "Schedule of depreciation rates" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Disclosure of derivative financial instruments [text block]", "terseLabel": "Derivative financial instruments" } }, "en": { "role": { "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r544" ] }, "adxn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about cash and cash equivalents", "label": "Disclosure of detailed information about cash and cash equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of intangible assets" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r72", "r274" ] }, "adxn_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about non-current financial assets", "label": "Disclosure of detailed information about non-current financial assets [Table Text Block]", "terseLabel": "Schedule of non-current financial assets" } } }, "auth_ref": [] }, "adxn_DisclosureOfDetailedInformationAboutOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfDetailedInformationAboutOtherCurrentAssetsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about other current assets", "label": "Disclosure of detailed information about other current assets [Table Text Block]", "terseLabel": "Schedule of other current assets" } } }, "auth_ref": [] }, "adxn_DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about payables and accruals", "label": "Disclosure of detailed information about payables and accruals [Table Text Block]", "terseLabel": "Schedule of payables and accruals" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of changes in equipment" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r14", "r242" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "terseLabel": "Revenue from contract with customer" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r121", "r200" ] }, "ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDiscontinuedOperationsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperations" ], "lang": { "en-us": { "role": { "label": "Disclosure of discontinued operations [text block]", "terseLabel": "Discontinued operations" } }, "en": { "role": { "documentation": "The disclosure of discontinued operations. [Refer: Discontinued operations [member]]" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShare" ], "lang": { "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Profit or loss per share" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r60" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureStaffCosts" ], "lang": { "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "terseLabel": "Staff costs" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r35" ] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformation" ], "lang": { "en-us": { "role": { "label": "Disclosure of entity's operating segments [text block]", "terseLabel": "Segment information" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r198" ] }, "adxn_DisclosureOfEstimatedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfEstimatedBenefitPaymentsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of estimated benefit payments", "label": "Disclosure of estimated benefit payments [Table Text Block]", "terseLabel": "Schedule of estimated benefit payments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDate" ], "lang": { "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Events after the balance sheet date" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r1" ] }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesByNatureExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of expenses by nature [text block]", "terseLabel": "Schedule of operating costs" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_DisclosureOfExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCosts" ], "lang": { "en-us": { "role": { "label": "Disclosure of expenses [text block]", "terseLabel": "Operating costs" } }, "en": { "role": { "documentation": "The disclosure of expenses." } } }, "auth_ref": [ "r544" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [text block]", "terseLabel": "Schedule of fair value measurement of assets" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of assets." } } }, "auth_ref": [ "r117", "r304" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of assets." } } }, "auth_ref": [ "r117", "r304" ] }, "adxn_DisclosureOfFairValueMeasurementOfDerivativeFinancialInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfFairValueMeasurementOfDerivativeFinancialInstrumentsTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of the fair value measurement of derivative financial instruments.", "label": "Disclosure of fair value measurement of derivative financial instruments [text block]", "terseLabel": "Schedule of fair value (level 3) of derivative financial instruments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]", "terseLabel": "Financial assets at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]" } } }, "auth_ref": [ "r314" ] }, "ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]", "terseLabel": "Financial assets at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value of investments in equity instruments designated at fair value through other comprehensive income." } } }, "auth_ref": [ "r314" ] }, "ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfPlanAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of plan assets [text block]", "terseLabel": "Schedule of fair value of plan assets" } }, "en": { "role": { "documentation": "The disclosure of the fair value of defined benefit plan assets. [Refer: Plan assets [member]; Defined benefit plans [domain]]" } } }, "auth_ref": [ "r29", "r252" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNet" ], "lang": { "en-us": { "role": { "label": "Disclosure of finance income (cost) [text block]", "verboseLabel": "Finance result, net" } } }, "auth_ref": [ "r544" ] }, "adxn_DisclosureOfFinanceIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfFinanceIncomeExpenseTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of finance income (expense)", "label": "Disclosure of finance income (expense) [Table Text Block]", "terseLabel": "Schedule of finance result, net" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Derivative financial instruments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagement" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial risk management [text block]", "terseLabel": "Financial risk management" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r544" ] }, "adxn_DisclosureOfFundingOfDefinedBenefitPensionsAndActuarialAdjustmentsOnPlanLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfFundingOfDefinedBenefitPensionsAndActuarialAdjustmentsOnPlanLiabilitiesTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of funding of defined benefit pensions and actuarial adjustments on plan liabilities", "label": "Disclosure of funding of defined benefit pensions and actuarial adjustments on plan liabilities [Table Text Block]", "terseLabel": "Schedule of components of the costs recognized in other comprehensive income" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureGeneralInformation" ], "lang": { "en-us": { "role": { "label": "Disclosure of general information about financial statements [text block]", "terseLabel": "General information" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r216", "r324" ] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [text block]", "terseLabel": "Schedule of geographical areas" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r196" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxes" ], "lang": { "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Taxes" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of information about key management personnel [text block]", "terseLabel": "Schedule of key management compensation" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r544" ] }, "adxn_DisclosureOfInputsToOptionPricingModelTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfInputsToOptionPricingModelTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inputs to option pricing model", "label": "Disclosure of inputs to option pricing model [Table Text Block]", "terseLabel": "Schedule of inputs to option pricing model" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r74" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r72", "r274" ] }, "ifrs-full_DisclosureOfInterestsInAssociatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInterestsInAssociatesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociates" ], "lang": { "en-us": { "role": { "label": "Disclosure of interests in associates [text block]", "terseLabel": "Interests in associates" } }, "en": { "role": { "documentation": "The disclosure of interests in associates. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r95" ] }, "adxn_DisclosureOfLeaseLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfLeaseLiabilitiesTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of lease liabilities", "label": "Disclosure of lease liabilities [Table Text Block]", "terseLabel": "Schedule of lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Summary of material accounting policies" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r226", "r310", "r321" ] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]", "terseLabel": "Financial risk management" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments." } } }, "auth_ref": [ "r172", "r173" ] }, "adxn_DisclosureOfNetDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfNetDebtTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of net debt", "label": "Disclosure of net debt [Table Text Block]", "terseLabel": "Schedule of net debt" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of net defined benefit liability (asset) [text block]", "terseLabel": "Schedule of movement in defined benefit obligations and plan assets" } }, "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r21", "r246" ] }, "adxn_DisclosureOfNonCurrentFinancialAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfNonCurrentFinancialAssetsTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssets" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of non-current financial assets", "label": "Disclosure of non-current financial assets [Text Block]", "terseLabel": "Non-current financial assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Events after the balance sheet date" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]", "terseLabel": "Events after balance sheet date" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r0", "r230" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Schedule of movements in number of options outstanding" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r153", "r289" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]", "terseLabel": "Schedule of outstanding share options" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r154" ] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Segment information" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [line items]", "terseLabel": "Segments" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } } }, "auth_ref": [ "r189" ] }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current assets [text block]", "terseLabel": "Other current assets" } }, "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } } }, "auth_ref": [ "r544" ] }, "adxn_DisclosureOfOtherCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfOtherCurrentAssetsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of other current assets", "label": "Disclosure of other current assets [Line Items]", "terseLabel": "Other current assets" } } }, "auth_ref": [] }, "adxn_DisclosureOfOtherCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfOtherCurrentAssetsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of other current assets", "label": "Disclosure of other current assets [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncome" ], "lang": { "en-us": { "role": { "label": "Disclosure of other operating income [text block]", "terseLabel": "Other income" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_DisclosureOfProductsAndServicesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProductsAndServicesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of products and services [text block]", "terseLabel": "Schedule of revenue from contract with customer and other income by nature" } }, "en": { "role": { "documentation": "The disclosure of the entity's products and services. [Refer: Products and services [domain]]" } } }, "auth_ref": [ "r194" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipment" ], "lang": { "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "Equipment" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r17" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "terseLabel": "Equipment" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r14", "r242" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract", "lang": { "en-us": { "role": { "label": "Right-of-use assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [text block]", "terseLabel": "Schedule of right-of-use assets" } }, "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r133", "r208" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]", "terseLabel": "Right-of-use assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } } }, "auth_ref": [ "r133", "r208" ] }, "adxn_DisclosureOfReconciliationOfEffectiveTaxRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfReconciliationOfEffectiveTaxRateTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of reconciliation of effective tax rate", "label": "Disclosure of reconciliation of effective tax rate [Table Text Block]", "terseLabel": "Schedule of reconciliation of income tax" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related party transactions" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r47" ] }, "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomer" ], "lang": { "en-us": { "role": { "label": "Disclosure of revenue from contracts with customers [text block]", "terseLabel": "Revenue from contract with customer" } }, "en": { "role": { "documentation": "The entire disclosure for revenue from contracts with customers." } } }, "auth_ref": [ "r124", "r125" ] }, "adxn_DisclosureOfRightOfUseAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfRightOfUseAssetsTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssets" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of right-of-use assets", "label": "Disclosure of right-of-use assets [Text Block]", "terseLabel": "Right-of-use assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSegmentsMajorCustomersExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of major customers [text block]", "terseLabel": "Schedule of revenue from contract with customer and other income by major counterparties" } }, "en": { "role": { "documentation": "The disclosure of major customers." } } }, "auth_ref": [ "r197" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]", "terseLabel": "Actuarial assumptions" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions." } } }, "auth_ref": [ "r32" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapital" ], "lang": { "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r222", "r309", "r345" ] }, "adxn_DisclosureOfShareOptionsGrantedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfShareOptionsGrantedTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of share options granted", "label": "Disclosure of share options granted [Table Text Block]", "terseLabel": "Schedule of share options granted" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "Share-based compensation" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r146" ] }, "ifrs-full_DisclosureOfSignificantActuarialAssumptionsUsedToDeterminePresentValueOfDefinedBenefitObligationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantActuarialAssumptionsUsedToDeterminePresentValueOfDefinedBenefitObligationExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant actuarial assumptions used to determine present value of defined benefit obligation [text block]", "terseLabel": "Schedule of principal actuarial assumptions for employment benefit obligations" } }, "en": { "role": { "documentation": "The disclosure of significant actuarial assumptions used to determine the present value of the defined benefit obligation." } } }, "auth_ref": [ "r30", "r253" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesAbstract", "lang": { "en-us": { "role": { "label": "Interests in associates" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [text block]", "terseLabel": "Schedule of carrying amount and financial information of equity-accounted investments" } }, "en": { "role": { "documentation": "The disclosure of associates. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r51", "r53", "r111", "r300" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesConsolidationAndSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [line items]", "terseLabel": "General information", "verboseLabel": "Material accounting estimates and judgments" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesConsolidationAndSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to associates." } } }, "auth_ref": [ "r51", "r53", "r111", "r300" ] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of assets [text block]", "terseLabel": "Schedule of significant unobservable inputs used in fair value measurement" } }, "en": { "role": { "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of assets." } } }, "auth_ref": [ "r114" ] }, "adxn_DisclosureOfStaffCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfStaffCostsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureStaffCostsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of staff costs", "label": "Disclosure of staff costs [Table Text Block]", "terseLabel": "Schedule of staff costs" } } }, "auth_ref": [] }, "adxn_DisclosureOfTaxLossesCarryForwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisclosureOfTaxLossesCarryForwardsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of tax losses carry forwards", "label": "Disclosure of tax losses carry forwards [Table Text Block]", "terseLabel": "Schedule of tax losses carry forwards" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "terseLabel": "Deferred taxes", "verboseLabel": "Taxes" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r7", "r236" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "label": "Share-based compensation" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "terseLabel": "Share-based compensation" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r155", "r290" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAndAccruals" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Payables and accruals" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]", "verboseLabel": "Related party transactions" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r45", "r263" ] }, "ifrs-full_DiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DiscontinuedOperationsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureTaxesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Discontinued operations [member]", "terseLabel": "Discontinued operations" } }, "en": { "role": { "documentation": "This member stands for a component of an entity that either has been disposed of or is classified as held for sale, and that: (a) represents a separate major line of business or geographical area of operations; (b) is part of a single co-ordinated plan to dispose of a separate major line of business or geographical area of operations; or (c) is a subsidiary acquired exclusively with a view to resale. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r168" ] }, "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsConsideration", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "ifrs-full_GainLossRecognisedOnMeasurementToFairValueLessCostsToSellOrOnDisposalOfAssetsOrDisposalGroupsConstitutingDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of consideration for disposal of discontinued operations.", "label": "Disposal Of Noncurrent Assets Or Disposal Groups Classified As Held For Sale And Discontinued Operations, Consideration", "totalLabel": "Total disposal consideration" } } }, "auth_ref": [] }, "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsCosts", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "ifrs-full_GainLossRecognisedOnMeasurementToFairValueLessCostsToSellOrOnDisposalOfAssetsOrDisposalGroupsConstitutingDiscontinuedOperation", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of costs related to disposal of discontinued operations.", "label": "Disposal Of Noncurrent Assets Or Disposal Groups Classified As Held For Sale And Discontinued Operations, Costs", "negatedTotalLabel": "Total costs related to activities sold" } } }, "auth_ref": [] }, "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsOtherConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsOtherConsideration", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsConsideration", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of other consideration for disposal of discontinued operations.", "label": "Disposal Of Noncurrent Assets Or Disposal Groups Classified As Held For Sale And Discontinued Operations, Other Consideration", "terseLabel": "Other consideration" } } }, "auth_ref": [] }, "ifrs-full_DisposalsRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsRightofuseAssets", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposals to Right-of-Use Assets", "negatedLabel": "Disposals" } }, "en": { "role": { "documentation": "The decrease in right-of-use assets resulting from disposals. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r514" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r404" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r403", "r404", "r427" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r403", "r404", "r427", "r470" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r398" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r404" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r448" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r459" ] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "EUR", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "EUR", "terseLabel": "EUR" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss per share" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of profit or loss per share" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r55" ] }, "ifrs-full_EarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings per share [line items]", "terseLabel": "Profit or loss per share" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings per share [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to earnings per share." } } }, "auth_ref": [ "r55" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange difference on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r82", "r83" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosureStaffCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Employee benefits expense", "terseLabel": "Staff costs (note 18)", "totalLabel": "Total staff costs", "verboseLabel": "Staff costs" } } }, "auth_ref": [ "r217", "r315", "r356", "r391" ] }, "adxn_EmployeeShareOptionPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "EmployeeShareOptionPlansMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "documentation": "Employee share option plans", "label": "Employee share option plans (ESOP)" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r400" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r400" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r400" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r510" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r400" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r400" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r511" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r453" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r506" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r506" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r506" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r91", "r93", "r112", "r113", "r115", "r264", "r281", "r302", "r303", "r313", "r332", "r340" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "auth_ref": [] }, "ifrs-full_EquityInstrumentsPercentageContributedToFairValueOfPlanAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityInstrumentsPercentageContributedToFairValueOfPlanAssets", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails": { "parentTag": "adxn_AllAssetsPercentageContributedToFairValueOfPlanAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Equity instruments, percentage contributed to fair value of plan assets", "terseLabel": "Equity instruments" } }, "en": { "role": { "documentation": "The percentage equity instruments contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [domain]] [Contrast: Equity instruments, amount contributed to fair value of plan assets]" } } }, "auth_ref": [ "r518" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r463" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r420", "r431", "r441", "r474" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r417", "r428", "r438", "r471" ] }, "ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EstimateOfContributionsExpectedToBePaidToPlan", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails" ], "lang": { "en-us": { "role": { "label": "Estimate of contributions expected to be paid to plan for next annual reporting period", "terseLabel": "Estimate of contributions expected to be paid to plan for next annual reporting period" } }, "en": { "role": { "documentation": "The estimate of the expected contributions to be made to a defined benefit plan for the next annual reporting period. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r33", "r34", "r254" ] }, "adxn_EstimatedDefinedBenefitPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "EstimatedDefinedBenefitPayments", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Estimated defined benefit payments", "label": "Estimated defined benefit payments", "terseLabel": "Estimated defined benefit payments" } } }, "auth_ref": [] }, "ifrs-full_EstimatedFinancialEffectOfContingentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EstimatedFinancialEffectOfContingentAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Estimated financial effect of contingent assets", "terseLabel": "Remaining contingent consideration receivable" } }, "en": { "role": { "documentation": "The amount of the estimated financial effect of possible assets that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within control of the entity." } } }, "auth_ref": [ "r67", "r269" ] }, "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EstimatedFinancialEffectOfContingentLiabilities", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureCommitmentsAndContingenciesCapitalCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Estimated financial effect of contingent liabilities", "terseLabel": "Outstanding litigation" } }, "en": { "role": { "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r66", "r268" ] }, "adxn_EurostarsInnosuisseMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "EurostarsInnosuisseMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Eurostars (Innosuisse)", "label": "Eurostars/Innosuisse", "terseLabel": "Eurostars/Innosuisse" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r469" ] }, "adxn_ExerciseOfPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ExerciseOfPreFundedWarrants", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise of pre-funded warrants", "label": "Exercise of pre-funded warrants" } } }, "auth_ref": [] }, "adxn_ExercisePeriodOfOptionsGranted": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ExercisePeriodOfOptionsGranted", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise period of options granted", "label": "Exercise period of options granted" } } }, "auth_ref": [] }, "adxn_ExercisePeriodOfWarrants": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ExercisePeriodOfWarrants", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The exercise period of warrants.", "label": "Exercise Period Of Warrants", "terseLabel": "Exercise period of warrants granted", "verboseLabel": "Exercise period of warrants received on investment in Stalicla SA" } } }, "auth_ref": [] }, "adxn_ExercisePriceOfIssuedWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ExercisePriceOfIssuedWarrants", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price of issued warrants", "label": "Exercise price of granted warrants" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price, share options granted", "terseLabel": "Weighted average strike price per share" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r156" ] }, "adxn_ExpenseFromShareBasedPaymentIncludingAcceleratedVestingCostsOfEquityIncentiveUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ExpenseFromShareBasedPaymentIncludingAcceleratedVestingCostsOfEquityIncentiveUnits", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Expense recognised for sharebased payment transactions in which the goods or services received did not qualify for recognition as assets, including costs arising from accelerated vesting of employees' equity incentive units.", "label": "Expense from Share Based Payment Including Accelerated Vesting Costs of Equity Incentive Units", "terseLabel": "Share-based compensation expense including accelerated vesting of employees equity incentive units" } } }, "auth_ref": [] }, "adxn_ExpenseFromShareBasedTransactionsIfCalculatedOnHigherReasonablyPossibleAssumptions": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ExpenseFromShareBasedTransactionsIfCalculatedOnHigherReasonablyPossibleAssumptions", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Expense from share-based transactions, if calculated on higher reasonably possible assumptions", "label": "Expense from share-based transactions, if calculated on higher reasonably possible assumptions", "terseLabel": "Expense from share-based transactions, if calculated on higher reasonably possible assumptions" } } }, "auth_ref": [] }, "adxn_ExpenseFromShareBasedTransactionsIfCalculatedOnLowerReasonablyPossibleAssumptions": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ExpenseFromShareBasedTransactionsIfCalculatedOnLowerReasonablyPossibleAssumptions", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Expense from share-based transactions, if calculated on lower reasonably possible assumptions", "label": "Expense from share-based transactions, if calculated on lower reasonably possible assumptions", "terseLabel": "Expense from share-based transactions, if calculated on lower reasonably possible assumptions" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets", "terseLabel": "Expense from share-based payment transactions", "verboseLabel": "Share-based compensation" } } }, "auth_ref": [ "r160", "r291" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureStaffCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureStaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "terseLabel": "Value of share-based services" } } }, "auth_ref": [ "r547" ] }, "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Expense relating to short-term leases for which recognition exemption has been used", "terseLabel": "Short term leases" } } }, "auth_ref": [ "r130", "r205" ] }, "adxn_ExpensesRecognisedForServicesReceivedAtZeroCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ExpensesRecognisedForServicesReceivedAtZeroCosts", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expenses recognised for services received at zero costs.", "label": "Expenses Recognised For Services Received At Zero Costs", "terseLabel": "Fair value of services received at zero cost recorded as other operating cost", "verboseLabel": "Fair value of services received at zero costs" } } }, "auth_ref": [] }, "adxn_ExpirationPeriodForOptions": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ExpirationPeriodForOptions", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails" ], "lang": { "en-us": { "role": { "documentation": "Expiration period for options", "label": "Expiration period for options" } } }, "auth_ref": [] }, "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Explanation of effect of share-based payments on entity's profit or loss [text block]", "terseLabel": "Schedule of effect of share-based compensation on profit or loss" } }, "en": { "role": { "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)." } } }, "auth_ref": [ "r159" ] }, "ifrs-full_ExternalCreditGradesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExternalCreditGradesAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "External credit grades [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r375", "r381", "r388" ] }, "ifrs-full_ExternalCreditGradesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExternalCreditGradesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "External credit grades [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'External credit grades' axis if no other member is used." } } }, "auth_ref": [ "r375", "r381", "r388" ] }, "adxn_ExternalResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ExternalResearchAndDevelopmentCosts", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "External research and development costs", "label": "External research and development costs", "terseLabel": "External research and development costs" } } }, "auth_ref": [] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "FR", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "FRANCE", "terseLabel": "France" } } }, "auth_ref": [] }, "adxn_FairValueOfServiceAgreementIncludedInCalculationOfGainOrLossOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "FairValueOfServiceAgreementIncludedInCalculationOfGainOrLossOnTransaction", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsConsideration", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Fair value of service agreement included in calculation of gain or loss on transaction", "label": "Fair value of service agreement included in calculation of gain or loss on transaction", "terseLabel": "Fair value of service agreement" } } }, "auth_ref": [] }, "adxn_FairValueOfServiceAgreementProvidedAfterDisposalOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "FairValueOfServiceAgreementProvidedAfterDisposalOfDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of service agreement provided after disposal of discontinued operation", "label": "Fair value of service agreement provided after disposal of discontinued operation", "terseLabel": "Fair value of service agreement" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Finance costs.", "negatedLabel": "Finance expense" } } }, "auth_ref": [ "r350" ] }, "adxn_FinanceCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "FinanceCostsAbstract", "lang": { "en-us": { "role": { "documentation": "Finance costs", "label": "Finance result, net" } } }, "auth_ref": [] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Finance income" } } }, "auth_ref": [ "r552" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Finance income (cost)", "totalLabel": "Finance result" } } }, "auth_ref": [ "r552" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets", "negatedTerseLabel": "Expected loss allowance" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r171", "r174", "r175", "r177", "r297", "r298", "r299", "r376" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Financial assets at fair value through other comprehensive income" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets at fair value through other comprehensive income, category [member]", "terseLabel": "Financial assets at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through other comprehensive income category. [Refer: Financial assets at fair value through other comprehensive income]" } } }, "auth_ref": [ "r181", "r294" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets at fair value through profit or loss, category [member]", "terseLabel": "Financial assets at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r180", "r293" ] }, "adxn_FinancialRiskManagementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "FinancialRiskManagementAbstract", "lang": { "en-us": { "role": { "documentation": "Financial risk management", "label": "Financial risk management" } } }, "auth_ref": [] }, "ifrs-full_FixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FixturesAndFittingsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and fixtures", "terseLabel": "Furniture and fixtures" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r359" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r424", "r435", "r445", "r478" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r424", "r435", "r445", "r478" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r424", "r435", "r445", "r478" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r424", "r435", "r445", "r478" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r424", "r435", "r445", "r478" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r458" ] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "GBP", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "GBP", "terseLabel": "GBP" } } }, "auth_ref": [] }, "adxn_GainLossOnDiscontinuanceNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "GainLossOnDiscontinuanceNetOfTax", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_ProfitLossFromDiscontinuedOperations", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The amount of gain (loss), net of tax on discontinuance when operations are discontinued.", "label": "Gain (Loss) On Discontinuance, Net Of Tax", "terseLabel": "Net gain on Neurosterix Transaction", "totalLabel": "Net gain on sale after income tax", "verboseLabel": "Net gain / (loss) of the sale of activities after income tax" } } }, "auth_ref": [] }, "adxn_GainLossOnDiscontinuanceNetOfTaxNonCashItems": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "GainLossOnDiscontinuanceNetOfTaxNonCashItems", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The amount of non-cash items of gain (loss), net of tax on discontinuance when operations are discontinued.", "label": "Gain (Loss) On Discontinuance, Net Of Tax, Non-cash Items", "terseLabel": "Net gain on Neurosterix Transaction, non-cash items" } } }, "auth_ref": [] }, "ifrs-full_GainLossRecognisedOnMeasurementToFairValueLessCostsToSellOrOnDisposalOfAssetsOrDisposalGroupsConstitutingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossRecognisedOnMeasurementToFairValueLessCostsToSellOrOnDisposalOfAssetsOrDisposalGroupsConstitutingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_GainLossOnDiscontinuanceNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Gain (loss) recognised on measurement to fair value less costs to sell or on disposal of assets or disposal groups constituting discontinued operation", "totalLabel": "Net gain on sale before income tax" } } }, "auth_ref": [ "r164" ] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain (loss)", "terseLabel": "Foreign exchange gains /(losses)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r37", "r256", "r323" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administration" } } }, "auth_ref": [ "r547" ] }, "adxn_GeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "GeneralAndAdministrativeExpensesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "General and administration expenses", "label": "General and administrative expenses [member]", "terseLabel": "General and administration expense" } } }, "auth_ref": [] }, "adxn_GeneralInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "GeneralInformationAbstract", "lang": { "en-us": { "role": { "documentation": "General information", "label": "General information" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r196", "r360", "r372", "r374", "r386" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r196", "r360", "r372", "r374", "r386" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Cost", "terseLabel": "Cost" } } }, "auth_ref": [ "r10", "r68", "r77", "r80", "r161", "r175", "r177", "r238", "r270", "r277", "r280", "r298", "r299", "r376" ] }, "ifrs-full_GrossLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossLeaseLiabilities", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Gross lease liabilities", "terseLabel": "Lease liabilities - cash outflow" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r134", "r209", "r379" ] }, "adxn_GrossProceedsFromDisposalOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "GrossProceedsFromDisposalOfDiscontinuedOperation", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsConsideration", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross proceeds from disposal of discontinued operation", "label": "Gross proceeds from disposal of discontinued operation", "terseLabel": "Gross proceeds in cash received from Neurosterix Transaction", "verboseLabel": "Cash in from Neurosterix Pharma Sarl sale" } } }, "auth_ref": [] }, "adxn_GrossProceedsFromSaleOfTreasurySharesExcludingLiquidityAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "GrossProceedsFromSaleOfTreasurySharesExcludingLiquidityAgreement", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross proceeds from sale of treasury shares, excluding liquidity agreement", "label": "Gross proceeds from sale of treasury shares, excluding liquidity agreement", "terseLabel": "Gross proceeds from sale of treasury shares, excluding liquidity agreement" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r403", "r404", "r427" ] }, "adxn_IfrsBalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IfrsBalanceSheetLocationAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Balance sheet location", "label": "IFRS Balance sheet location [Axis]" } } }, "auth_ref": [] }, "adxn_IfrsEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IfrsEquipmentMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Equipment", "label": "Equipment" } } }, "auth_ref": [] }, "adxn_IfrsOtherIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IfrsOtherIncomeAbstract", "lang": { "en-us": { "role": { "documentation": "Other income", "label": "Other income" } } }, "auth_ref": [] }, "adxn_IfrsResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IfrsResearchMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Research", "label": "Research", "terseLabel": "Research" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLoss", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment loss" } }, "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r62", "r63" ] }, "adxn_IncomeRecognisedForServicesReceivedAtZeroCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncomeRecognisedForServicesReceivedAtZeroCosts", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of income recognised for services received at zero costs.", "label": "Income Recognised For Services Received At Zero Costs", "terseLabel": "Fair value of Income recognised for services received at zero cost", "verboseLabel": "Fair value of services received at zero cost from Neurosterix Group" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Profit or Loss" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossFromContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Tax expense (income)", "negatedTerseLabel": "Income tax expense" } } }, "auth_ref": [ "r2", "r3", "r4", "r49", "r110", "r188", "r231", "r232", "r233", "r351" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Decrease in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r86", "r224" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents, discontinued operations", "totalLabel": "Net cash from / (used in) discontinued activities" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents from discontinued operations. [Refer: Cash and cash equivalents; Discontinued operations [member]]" } } }, "auth_ref": [ "r541" ] }, "adxn_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumptionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumptionPercentage", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption, percentage", "label": "Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption, percentage", "terseLabel": "Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption, percentage" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumptionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumptionPercentage", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption, percentage", "label": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption, percentage", "terseLabel": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption, percentage" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInDepreciationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInDepreciationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in depreciation of intangible assets.", "label": "Increase (Decrease) in Depreciation of Intangible Assets", "terseLabel": "Increase (decrease) in depreciation of intangible assets" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInDirectorsAndOfficersInsuranceLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInDirectorsAndOfficersInsuranceLiability", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in insurance costs due to higher directors and officer's liability insurance premiums.", "label": "Increase (decrease) in Directors and Officers Insurance Liability", "terseLabel": "Increase (decrease) in D&O insurance" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInEquityDueToReasonablyPossibleDecreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInEquityDueToReasonablyPossibleDecreaseInDesignatedRiskComponent", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in equity due to reasonably possible decrease in designated risk component", "label": "Increase (decrease) in equity due to reasonably possible decrease in designated risk component", "terseLabel": "Increase (decrease) in shareholders' equity due to reasonably possible decrease in risk assumption" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInEquityDueToReasonablyPossibleIncreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInEquityDueToReasonablyPossibleIncreaseInDesignatedRiskComponent", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in equity due to reasonably possible increase in designated risk component", "label": "Increase (decrease) in equity due to reasonably possible increase in designated risk component", "terseLabel": "Increase (decrease) in shareholders' equity due to reasonably possible increase in risk assumption" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInExternalResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInExternalResearchAndDevelopmentCosts", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in external research and development costs.", "label": "Increase (Decrease) in External Research and Development Costs", "terseLabel": "Increase (decrease) in external research and development costs" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible decrease in an unobservable input." } } }, "auth_ref": [ "r116" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input." } } }, "auth_ref": [ "r116" ] }, "adxn_IncreaseDecreaseInOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInOperatingExpenses", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating costs.", "label": "Increase (Decrease) in Operating Expenses", "terseLabel": "Increase (decrease) in total operating costs" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInOtherCurrentAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInOtherCurrentAsset", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in other current assets", "label": "Increase (decrease) in other current assets", "terseLabel": "Increase (decrease) in other current assets" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInPayablesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInPayablesAndAccruals", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in payables and accruals", "label": "Increase (decrease) in payables and accruals" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleDecreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleDecreaseInDesignatedRiskComponent", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in profit or loss due to reasonably possible decrease in designated risk component", "label": "Increase (decrease) in profit or loss due to reasonably possible decrease in designated risk component", "terseLabel": "Increase (decrease) in net income due to reasonably possible decrease in risk assumption" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleIncreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleIncreaseInDesignatedRiskComponent", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in profit or loss due to reasonably possible increase in designated risk component", "label": "Increase (decrease) in profit or loss due to reasonably possible increase in designated risk component", "terseLabel": "Increase (decrease) in net income due to reasonably possible increase in risk assumption" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInSurplusOfDefinedBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInSurplusOfDefinedBenefitPlan", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in surplus of defined benefit plan", "label": "Increase (decrease) in surplus of defined benefit plan", "negatedLabel": "Increase (decrease) in shortfall of defined benefit plan" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInUnrecordedTaxLossesCarryForwards": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseInUnrecordedTaxLossesCarryForwards", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in unrecorded tax losses carry forwards", "label": "Increase (decrease) in unrecorded tax losses carry forwards", "terseLabel": "Increase in unrecorded tax losses carry forwards" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseThroughAssetsTransferredNetDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseThroughAssetsTransferredNetDebt", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in net debt through assets transferred.", "label": "Increase (Decrease) Through Assets Transferred, Net Debt", "negatedLabel": "Assets transferred to Neurosterix Pharma Sarl" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseThroughCashFlowsNetDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseThroughCashFlowsNetDebt", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through cash flows, net debt", "label": "Increase (decrease) through cash flows, net debt", "negatedTerseLabel": "Cash flows" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseThroughDisposalsNetDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseThroughDisposalsNetDebt", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in net debt through disposals.", "label": "Increase (Decrease)Through Disposals, Net Debt", "negatedLabel": "Disposal" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesNetDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesNetDebt", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through effect of changes in foreign exchange rates, net debt", "label": "Increase (decrease) through effect of changes in foreign exchange rates, net debt", "negatedLabel": "Foreign exchange differences" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfOptions", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through exercise of options, equity", "terseLabel": "Exercise ESOP (treasury shares IFRS 2)" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } } }, "auth_ref": [ "r546" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through exercise of warrants, equity", "terseLabel": "Exercise of pre-funded warrants" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r546" ] }, "adxn_IncreaseDecreaseThroughIssuanceOfWarrantsAndPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseThroughIssuanceOfWarrantsAndPreFundedWarrants", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in equity through grant of warrants and pre-funded warrants", "label": "Increase Decrease Through Grant Of Warrants And Pre Funded Warrants", "terseLabel": "Value of warrants" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseThroughModificationOfLeaseTermsNetDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseThroughModificationOfLeaseTermsNetDebt", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in net debt through modification of lease terms.", "label": "(Increase) Decrease Through Modification of Lease Terms Net Debt", "negatedLabel": "Effect of modification to lease terms" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseThroughModificationOfLeaseTermsToRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseThroughModificationOfLeaseTermsToRightOfUseAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) through modification of lease terms to right-of-use assets.", "label": "Increase (Decrease) Through Modification of Lease Terms to Right-of-Use Assets", "terseLabel": "Effect of lease modifications" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseThroughSaleOfPreFundedWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseDecreaseThroughSaleOfPreFundedWarrantsEquity", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through sale of pre-funded warrants", "label": "Sale of pre-funded warrants" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Value of share-based services" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r319" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through transfers, property, plant and equipment", "terseLabel": "Assets transferred to Neurosterix Pharma Srl" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r514" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersRightofuseAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease)Through Transfers Right of use Assets", "terseLabel": "Assets transferred to Neurosterix Pharma Srl" } }, "en": { "role": { "documentation": "The increase (decrease) in right-of-use assets resulting from transfers. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r514" ] }, "adxn_IncreaseInInterestsInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncreaseInInterestsInAssociates", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase in interests in associates", "label": "Increase in interests in associates", "terseLabel": "Fair value of Neurosterix US Holdings LLC equity interest" } } }, "auth_ref": [] }, "adxn_IncrementPeriodForExtensionOfResearchTerm": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IncrementPeriodForExtensionOfResearchTerm", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Increment period for extension of research term", "label": "Increment period for extension of research term", "terseLabel": "Increment period for extension of research term" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r424", "r435", "r445", "r469", "r478", "r482", "r490" ] }, "ifrs-full_IndividuallyInsignificantCounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IndividuallyInsignificantCounterpartiesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other counterparties" } }, "en": { "role": { "documentation": "This member stands for individually insignificant parties to the transaction other than the entity." } } }, "auth_ref": [ "r183" ] }, "adxn_IndiviorPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IndiviorPlcMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails", "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Indivior PLC", "label": "Indivior PLC", "terseLabel": "Indivior PLC" } } }, "auth_ref": [] }, "adxn_InitialResearchTerm": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "InitialResearchTerm", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial research term", "label": "Initial research term", "terseLabel": "Initial research term" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r488" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r405", "r494" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r405", "r494" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r405", "r494" ] }, "ifrs-full_InsuranceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InsuranceExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "label": "Insurance expense", "terseLabel": "D&O insurance" } } }, "auth_ref": [ "r547" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Closing amount", "periodStartLabel": "Opening amount", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r71", "r273", "r326" ] }, "adxn_InterestBearingDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "InterestBearingDebt", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Interest-bearing debt", "label": "Interest-bearing debt", "terseLabel": "Interest-bearing debt" } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interests cost" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r109", "r187", "r193" ] }, "ifrs-full_InterestExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Interest cost on defined benefit plans", "negatedLabel": "Interest cost" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense (income), net defined benefit liability (asset)", "negatedTerseLabel": "Interest (cost) income" } } }, "auth_ref": [ "r23", "r248" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense on lease liabilities", "negatedTerseLabel": "Interests expense on leases" } } }, "auth_ref": [ "r129", "r204" ] }, "ifrs-full_InterestIncomeDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Interest income on defined benefit plans", "terseLabel": "Interest income" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid, classified as financing activities", "negatedTerseLabel": "Interest paid" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r84" ] }, "adxn_InterestReceivedClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "InterestReceivedClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Interest received, classified as financing activities", "label": "Interest received, classified as financing activities", "terseLabel": "Interest received" } } }, "auth_ref": [] }, "adxn_InvestmentInDivestmentCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "InvestmentInDivestmentCompany", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of investment in divestment company.", "label": "Investment in Divestment Company", "negatedLabel": "Investment in Neurosterix Pharma Sarl" } } }, "auth_ref": [] }, "ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentsInAssociatesAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Investments in associates accounted for using equity method", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of the period", "terseLabel": "Investment accounted for using the equity method" } }, "en": { "role": { "documentation": "The amount of investments in associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method]" } } }, "auth_ref": [ "r549" ] }, "ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Investments in equity instruments designated at fair value through other comprehensive income [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Investments in equity instruments designated at fair value through other comprehensive income' axis if no other member is used." } } }, "auth_ref": [ "r314" ] }, "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Investments in equity instruments designated at fair value through other comprehensive income [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r314" ] }, "adxn_IssueOfSharesTreasuryShares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IssueOfSharesTreasuryShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Issue of shares-treasury shares", "label": "Issue of shares-treasury shares", "terseLabel": "Issuance of treasury shares" } } }, "auth_ref": [] }, "adxn_IssueOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "IssueOfTreasuryShares", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Issue of treasury shares", "label": "Issue of treasury shares" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r390", "r396" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share Capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r320" ] }, "adxn_JanssenPharmaceuticalsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "JanssenPharmaceuticalsInc.Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Janssen Pharmaceuticals Inc.", "label": "Janssen Pharmaceuticals Inc.", "terseLabel": "Janssen Pharmaceuticals Inc." } } }, "auth_ref": [] }, "adxn_January12023Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "January12023Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "January 1, 2023", "label": "January 1, 2023 [member]", "terseLabel": "January 1, 2023" } } }, "auth_ref": [] }, "adxn_July12023Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "July12023Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "July 1, 2023", "label": "July 1, 2023 [Member]", "terseLabel": "July 1, 2023" } } }, "auth_ref": [] }, "adxn_KeplerCapitalMarketsSaMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "KeplerCapitalMarketsSaMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Kepler Capital Markets SA", "label": "Kepler" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Key management compensation" } } }, "auth_ref": [ "r42", "r260" ] }, "adxn_KeyManagementPersonnelCompensationConsultingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "KeyManagementPersonnelCompensationConsultingFees", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation, consulting fees", "label": "Key management personnel compensation, consulting fees", "terseLabel": "Consulting fees" } } }, "auth_ref": [] }, "adxn_KeyManagementPersonnelCompensationSalariesOtherShortTermEmployeeBenefitsAndPostEmploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "KeyManagementPersonnelCompensationSalariesOtherShortTermEmployeeBenefitsAndPostEmploymentBenefits", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation, salaries, other short-term employee benefits and post-employment benefits", "label": "Key management personnel compensation, salaries, other short-term employee benefits and post-employment benefits", "terseLabel": "Salaries, other short-term employee benefits and post-employment benefits" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share-based compensation" } } }, "auth_ref": [ "r41" ] }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelOfEntityOrParentMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Board of Directors and Executive Management", "terseLabel": "Board of directors and executive management" } }, "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } } }, "auth_ref": [ "r44", "r262" ] }, "adxn_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for laboratory equipment.", "label": "Laboratory equipment", "terseLabel": "Laboratory equipment" } } }, "auth_ref": [] }, "ifrs-full_LandAndBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LandAndBuildingsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Properties" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]" } } }, "auth_ref": [ "r358" ] }, "adxn_LaterThanEightYearsAndNotLaterThanNineYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "LaterThanEightYearsAndNotLaterThanNineYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for later than eight years and not later than nine years.", "label": "Later than eight years and not later than nine years" } } }, "auth_ref": [] }, "adxn_LaterThanFiveYearsAndNotLaterThanSixYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "LaterThanFiveYearsAndNotLaterThanSixYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for later than five years and not later than six years.", "label": "Later than five years and not later than six years" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFiveYearsAndNotLaterThanTenYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Later than five years and not later than ten years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years and not later than ten years." } } }, "auth_ref": [ "r378", "r382", "r547" ] }, "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "label": "Later than four years and not later than five years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than four years and not later than five years." } } }, "auth_ref": [ "r135", "r136", "r145", "r378", "r382", "r547" ] }, "adxn_LaterThanNineYearsAndNotLaterThanTenYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "LaterThanNineYearsAndNotLaterThanTenYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Later than nine years and not later than ten years", "label": "Later than nine years and not later than ten years" } } }, "auth_ref": [] }, "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Later than one year and not later than five years", "terseLabel": "1 to 5 Years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than five years." } } }, "auth_ref": [ "r211", "r214", "r377", "r382" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "label": "Later than one year and not later than two years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r135", "r136", "r145", "r378", "r382", "r547" ] }, "adxn_LaterThanSevenYearsAndNotLaterThanEightYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "LaterThanSevenYearsAndNotLaterThanEightYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for later than seven years and not later than eight years.", "label": "Later than seven years and not later than eight years", "terseLabel": "Later than seven years and not later than eight years" } } }, "auth_ref": [] }, "adxn_LaterThanSixYearsAndNotLaterThanSevenYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "LaterThanSixYearsAndNotLaterThanSevenYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for later than six years and not later than seven years.", "label": "Later than six years and not later than seven years" } } }, "auth_ref": [] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "label": "Later than three years and not later than four years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } } }, "auth_ref": [ "r135", "r136", "r145", "r378", "r382", "r547" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "label": "Later than two years and not later than three years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } } }, "auth_ref": [ "r135", "r136", "r145", "r378", "r382", "r547" ] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities.", "verboseLabel": "Lease liabilities - carrying amount" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r127" ] }, "ifrs-full_LeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Lease liabilities" } } }, "auth_ref": [] }, "adxn_LeaseLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "LeaseLiabilitiesLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease liabilities", "label": "Lease liabilities [Line Items]", "terseLabel": "Lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Leases", "terseLabel": "Leases" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r365", "r366" ] }, "adxn_LeaseLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "LeaseLiabilitiesTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease liabilities", "label": "Lease liabilities [Table]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "terseLabel": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r64", "r65", "r113", "r267", "r303" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r29", "r113", "r303" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r29", "r113", "r303" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset)", "negatedPeriodEndLabel": "Net defined benefit (liability) asset at end of period", "negatedPeriodStartLabel": "Net defined benefit (liability) asset at beginning of period", "negatedTerseLabel": "Net defined benefit (liability) asset" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r21", "r246" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "terseLabel": "Long-term debt" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r549" ] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsDetails": { "parentTag": "ifrs-full_NoncurrentFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Long-term deposits", "terseLabel": "Security rental deposits" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r549" ] }, "adxn_MaintenanceOfPatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "MaintenanceOfPatentsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Maintenance of patents", "label": "Maintenance of patents [Member]", "terseLabel": "Maintenance of patents" } } }, "auth_ref": [] }, "ifrs-full_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorCustomersAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Major customers [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r197" ] }, "ifrs-full_MajorCustomersDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorCustomersDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Major customers [domain]" } }, "en": { "role": { "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used." } } }, "auth_ref": [ "r197" ] }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorOrdinaryShareTransactionsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Major ordinary share transaction", "terseLabel": "Sale of treasury shares" } }, "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r357", "r387" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementLeaseLiabilitiesDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r123", "r135", "r136", "r137", "r138", "r139", "r145", "r170", "r179", "r199", "r202", "r212", "r215", "r296", "r335", "r361", "r378" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementLeaseLiabilitiesDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r123", "r135", "r136", "r137", "r138", "r139", "r145", "r170", "r199", "r202", "r212", "r215", "r296", "r335", "r361", "r378", "r380" ] }, "adxn_MaturityPeriodOfPayables": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "MaturityPeriodOfPayables", "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity period of payables", "label": "Maturity period of payables" } } }, "auth_ref": [] }, "adxn_May122023Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "May122023Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "May 12, 2023", "label": "May 12, 2023 [Member]", "terseLabel": "May 12, 2023" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r461" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r461" ] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r75", "r79", "r112", "r279", "r302" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r75", "r79", "r112", "r279", "r302" ] }, "adxn_Mglu2NamProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "Mglu2NamProgramMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "mGlu2 NAM program", "label": "mGlu2 NAM program" } } }, "auth_ref": [] }, "adxn_MiscellaneousOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "MiscellaneousOtherCurrentAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 4.0 }, "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "The amount of miscellaneous current other assets.", "label": "Miscellaneous Other Current Assets", "verboseLabel": "Other short-term assets" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating income", "terseLabel": "Other service income" } } }, "auth_ref": [ "r547" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r481" ] }, "adxn_MovementInTreasurySharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "MovementInTreasurySharesAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Movement in treasury Shares", "label": "Movement in treasury Shares [Abstract]", "terseLabel": "Movement in treasury shares:" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r489" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r462" ] }, "ifrs-full_NetAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetAssetsLiabilities", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails" ], "lang": { "en-us": { "role": { "label": "Assets (liabilities)", "terseLabel": "Net assets" } }, "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } } }, "auth_ref": [ "r367", "r547" ] }, "ifrs-full_NetDebt": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDebt", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Net debt", "negatedPeriodEndLabel": "Net asset / (debt) ending balance", "negatedPeriodStartLabel": "Net asset / (debt) beginning balance" } }, "en": { "role": { "documentation": "The amount of net debt of the entity." } } }, "auth_ref": [ "r547" ] }, "adxn_NetDebtLiabilitiesRelatedToDivestedCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NetDebtLiabilitiesRelatedToDivestedCompany", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsConsideration", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Net debt liabilities related to divested company", "label": "Net debt liabilities related to divested company", "terseLabel": "Net debt liabilities related to Neurosterix Pharma Sarl (IFRS 16)" } } }, "auth_ref": [] }, "adxn_NetDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NetDebtLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Net debt", "label": "Net debt [Line Items]", "terseLabel": "Net debt" } } }, "auth_ref": [] }, "adxn_NetDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NetDebtTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Net debt", "label": "Net debt [Table]" } } }, "auth_ref": [] }, "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset) [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r21", "r246" ] }, "ifrs-full_NetDefinedBenefitLiabilityAssetDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset) [domain]" } }, "en": { "role": { "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r21", "r246" ] }, "adxn_NetGainOnDivestmentCompanyDerecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NetGainOnDivestmentCompanyDerecognition", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsConsideration", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of net gain on derecognition of divestment company.", "label": "Net Gain on Divestment Company Derecognition", "terseLabel": "Net gain on Neurosterix Pharma Sarl derecognition (IFRS 10)" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "adxn_NetSalesPurchasesOfTreasurySharesUnderLiquidityAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NetSalesPurchasesOfTreasurySharesUnderLiquidityAgreement", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Net sales (purchases) of treasury shares under liquidity agreement", "label": "Net sales (purchases) of treasury shares under liquidity agreement", "terseLabel": "Net sales / (purchases) under liquidity agreement" } } }, "auth_ref": [] }, "adxn_NeurosterixGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NeurosterixGroupMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Neurosterix Group", "label": "Neurosterix Group" } } }, "auth_ref": [] }, "adxn_NeurosterixPharmaSarlMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NeurosterixPharmaSarlMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Neurosterix Pharma Sarl", "label": "Neurosterix", "terseLabel": "Neurosterix Pharma Sarl" } } }, "auth_ref": [] }, "adxn_NeurosterixUsHoldingsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NeurosterixUsHoldingsLlcMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesConsolidationAndSegmentsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Neurosterix US Holdings LLC.", "label": "Neurosterix US Holdings LLC [Member]", "terseLabel": "Neurosterix US Holdings LLC" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r461" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r424", "r435", "r445", "r469", "r478" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r452" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r451" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r469" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r489" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r489" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r230" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r230" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "terseLabel": "Non-current assets", "totalLabel": "Total non-current assets", "verboseLabel": "Long-lived assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r99", "r336", "r368" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract", "lang": { "en-us": { "role": { "label": "Discontinued operations" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentDerivativeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDerivativeFinancialAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current derivative financial assets", "terseLabel": "Derivative financial instrument" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial assets. [Refer: Derivative financial assets]" } } }, "auth_ref": [ "r549" ] }, "ifrs-full_NoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current financial assets.", "terseLabel": "Non-current financial assets", "totalLabel": "Total non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r171" ] }, "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current financial assets at fair value through other comprehensive income", "terseLabel": "Financial assets at fair value through other comprehensive income", "verboseLabel": "Financial assets at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]" } } }, "auth_ref": [ "r181", "r294" ] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Non-current lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r127" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "terseLabel": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r101", "r337", "r368" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentRecognisedLiabilitiesDefinedBenefitPlan", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current net defined benefit liability", "terseLabel": "Retirement benefits obligations" } }, "en": { "role": { "documentation": "The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]" } } }, "auth_ref": [ "r549" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementLeaseLiabilitiesDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsEstimatedBenefitPaymentsDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "label": "Not later than one year", "terseLabel": "Less than 1 Year" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r135", "r136", "r145", "r210", "r213", "r334", "r378", "r382" ] }, "adxn_NumberOfCategoriesOfDilutivePotentialShares": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfCategoriesOfDilutivePotentialShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of categories of dilutive potential shares", "label": "Number of categories of dilutive potential shares", "terseLabel": "Number of categories of dilutive potential shares" } } }, "auth_ref": [] }, "adxn_NumberOfCategoriesOfFinancialAssets": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfCategoriesOfFinancialAssets", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of categories of financial assets", "label": "Number of categories of financial assets", "terseLabel": "Number of categories of financial assets" } } }, "auth_ref": [] }, "adxn_NumberOfDilutiveInstruments": { "xbrltype": "decimalItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfDilutiveInstruments", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of (units of) instruments that are dilutive", "label": "Number of dilutive instruments" } } }, "auth_ref": [] }, "adxn_NumberOfDistinctMaterialPromisesAndPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfDistinctMaterialPromisesAndPerformanceObligations", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of distinct material promises and performance obligations", "label": "Number of distinct material promises and performance obligations", "terseLabel": "Number of distinct material promises and performance obligations" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Granted" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r158", "r540" ] }, "adxn_NumberOfNewlyIdentifiedComponentsSelected": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfNewlyIdentifiedComponentsSelected", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of newly identified compounds selected", "label": "Number of newly identified compounds selected", "terseLabel": "Number of newly identified compounds selected" } } }, "auth_ref": [] }, "adxn_NumberOfOptionsGrantedToEmployeesAndExecutiveManagersTransferredOnDisposalOfOperations": { "xbrltype": "decimalItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfOptionsGrantedToEmployeesAndExecutiveManagersTransferredOnDisposalOfOperations", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of options granted to employees and Executive Managers transferred on disposal of operations", "label": "Number of options granted to employees and Executive Managers transferred on disposal of operations" } } }, "auth_ref": [] }, "adxn_NumberOfOptionsRepriced": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfOptionsRepriced", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of options repriced", "label": "Number of options repriced" } } }, "auth_ref": [] }, "adxn_NumberOfOrdinarySharesToWhoseProceedsPhantomSharesEntitlephantomSharesReceivedOnInvestment": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfOrdinarySharesToWhoseProceedsPhantomSharesEntitlephantomSharesReceivedOnInvestment", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares to whose proceeds phantom shares entitlePhantom shares received on investment", "label": "Number of ordinary shares to whose proceeds phantom shares entitlePhantom shares received on investment", "terseLabel": "Ordinary shares to proceeds from which phantom shares entitle" } } }, "auth_ref": [] }, "adxn_NumberOfOrdinarySharesToWhosePurchaseWarrantsEntitle": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfOrdinarySharesToWhosePurchaseWarrantsEntitle", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares to whose purchase warrants entitle", "label": "Ordinary shares to purchase of which warrants entitle" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedLabel": "Forfeited" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r540" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "verboseLabel": "Outstanding shares" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r540" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Outstanding share options" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r147", "r151", "r154", "r283", "r287" ] }, "adxn_NumberOfPensionSchemes": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfPensionSchemes", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPensionObligationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of pension schemes", "label": "Number of pension schemes", "terseLabel": "Number of pension schemes" } } }, "auth_ref": [] }, "adxn_NumberOfPreferredSharesToWhosePurchaseWarrantsEntitle": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfPreferredSharesToWhosePurchaseWarrantsEntitle", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of preferred shares to whose purchase warrants entitle", "label": "Preferred shares to purchase of which warrants entitle" } } }, "auth_ref": [] }, "adxn_NumberOfSegments": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfSegments", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesConsolidationAndSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments", "label": "Number of segments", "terseLabel": "Number of segments" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options exercisable in share-based payment arrangement", "terseLabel": "Exercisable" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r152", "r288" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options exercised in share-based payment arrangement", "negatedLabel": "Exercised" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r150", "r286" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "negatedLabel": "Forfeited" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r149", "r285" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "terseLabel": "Granted" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r148", "r284" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares issued", "periodEndLabel": "Number of shares at end of period", "periodStartLabel": "Number of shares at beginning of period" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r546" ] }, "adxn_NumberOfSharesIssuedIncludingIfrs2Shares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfSharesIssuedIncludingIfrs2Shares", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued including IFRS 2 shares", "label": "Number of common shares including IFRS 2 shares" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Number of shares at end of period", "periodStartLabel": "Number of shares at beginning of period", "terseLabel": "Number of outstanding shares" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r219", "r306", "r342" ] }, "adxn_NumberOfSharesOutstandingIncludingIfrs2Shares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfSharesOutstandingIncludingIfrs2Shares", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares outstanding including IFRS 2 shares", "label": "Number of shares including IFRS 2 shares" } } }, "auth_ref": [] }, "adxn_NumberOfSharesReclassedAsTreasurySharesUnderIfrs2SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfSharesReclassedAsTreasurySharesUnderIfrs2SharesOutstanding", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares reclassed as treasury shares under IFRS 2, shares outstanding", "label": "Number of shares reclassed as treasury shares under IFRS 2, shares outstanding", "negatedLabel": "Number of shares reclassed as treasury shares under IFRS 2", "verboseLabel": "Number of outstanding shares benefiting from DSPPP" } } }, "auth_ref": [] }, "adxn_NumberOfSharesReclassedAsTreasurySharesUnderIfrs2TreasuryShares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfSharesReclassedAsTreasurySharesUnderIfrs2TreasuryShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares reclassed as treasury shares under IFRS 2, treasury shares", "label": "Number of shares reclassed as treasury shares under IFRS 2, treasury shares", "negatedLabel": "Number of shares reclassed as treasury shares under IFRS 2" } } }, "auth_ref": [] }, "adxn_NumberOfSharesRegisteredInCommercialRegisterDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfSharesRegisteredInCommercialRegisterDuringPeriod", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares registered in commercial register during period", "label": "Number of shares registered in commercial register during period" } } }, "auth_ref": [] }, "adxn_NumberOfSharesRegisteredInTradeRegister": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfSharesRegisteredInTradeRegister", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares registered in trade register", "label": "Number of shares registered in commercial register" } } }, "auth_ref": [] }, "adxn_NumberOfSwissBanksUsed": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfSwissBanksUsed", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of Swiss banks used", "label": "Number of Swiss banks used" } } }, "auth_ref": [] }, "adxn_NumberOfTreasurySharesIncludingIfrs2Shares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfTreasurySharesIncludingIfrs2Shares", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares including IFRS 2 shares", "label": "Number of treasury shares including IFRS 2 shares", "negatedLabel": "Number of shares including IFRS 2 shares" } } }, "auth_ref": [] }, "adxn_NumberOfTreasurySharesSoldPurchased": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfTreasurySharesSoldPurchased", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares sold (purchased)", "label": "Number of treasury shares sold (purchased)", "terseLabel": "Movement of shares under liquidity agreement" } } }, "auth_ref": [] }, "adxn_NumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "NumberOfWarrantsIssued", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued", "label": "Number of warrants granted" } } }, "auth_ref": [] }, "adxn_OperatingCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "OperatingCostsAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "documentation": "Operating costs", "label": "Operating costs" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails", "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Operating expense", "negatedTotalLabel": "Total operating costs", "totalLabel": "Total operating costs", "verboseLabel": "Operating costs" } } }, "auth_ref": [ "r552" ] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common shares" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r551" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive loss for the year", "totalLabel": "Other comprehensive income / (loss) for the period, net of tax", "verboseLabel": "Other comprehensive gain / (loss)" } } }, "auth_ref": [ "r106", "r318", "r347", "r354" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income [abstract]", "terseLabel": "Other comprehensive income / (loss)" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Exchange difference on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r338", "r354" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "totalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r338", "r354", "r515" ] }, "adxn_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansContinuingOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset) attributable to continuing operations.", "label": "Other Comprehensive Income, Net Of Tax, Gains (Losses) On Remeasurements Of Defined Benefit Plans, Continuing Operations", "terseLabel": "Remeasurements of retirement benefits obligation related to continuing operations" } } }, "auth_ref": [] }, "adxn_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansDiscontinuedOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset) attributable to discontinued operations.", "label": "Other Comprehensive Income, Net Of Tax, Gains (Losses) On Remeasurements Of Defined Benefit Plans, Discontinued Operations", "terseLabel": "Remeasurements of retirement benefits obligation related to discontinued operations" } } }, "auth_ref": [] }, "adxn_OtherCreditGradesMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "OtherCreditGradesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other credit grades", "label": "Other credit grades [member]", "terseLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other current assets.", "totalLabel": "Total other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r549" ] }, "adxn_OtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "OtherCurrentAssetsAbstract", "lang": { "en-us": { "role": { "documentation": "Other current assets", "label": "Other current assets" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentFinancialAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current financial assets", "terseLabel": "Other financial assets" } }, "en": { "role": { "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_OtherEquityInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherEquityInterest", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other equity interest", "terseLabel": "Other equity" } }, "en": { "role": { "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r390", "r396" ] }, "ifrs-full_OtherEquityInterestMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherEquityInterestMember", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Other equity interest [member]", "terseLabel": "Other Equity" } }, "en": { "role": { "documentation": "This member stands for equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r320" ] }, "ifrs-full_OtherExpenseByNature": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherExpenseByNature", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 5.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "label": "Other expenses, by nature", "verboseLabel": "Other operating costs" } } }, "auth_ref": [ "r356", "r391" ] }, "adxn_OtherFinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "OtherFinancialAssetsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementNetDebtDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other financial assets.", "label": "Other financial assets", "terseLabel": "Other financial assets" } } }, "auth_ref": [] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Other income.", "terseLabel": "Other income" } } }, "auth_ref": [ "r48", "r391", "r392" ] }, "adxn_OtherIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "OtherIncomeLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Other income", "label": "Other income [Line Items]", "terseLabel": "Other income" } } }, "auth_ref": [] }, "adxn_OtherIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "OtherIncomeTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Other income", "label": "Other income [Table]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r461" ] }, "adxn_OtherReserveMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "OtherReserveMember", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Other reserves, excluding treasury shares and foreign currency translation", "label": "Other Reserves" } } }, "auth_ref": [] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other reserves.", "terseLabel": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r390", "r396" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r422", "r433", "r443", "r476" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r425", "r436", "r446", "r479" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r425", "r436", "r446", "r479" ] }, "adxn_P1Or1Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "P1Or1Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "P-1 rating by Moody's or A-1 rating by Standard & Poor's", "label": "P-1 / A-1", "terseLabel": "P-1 / A-1" } } }, "auth_ref": [] }, "adxn_P2OrA2Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "P2OrA2Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "P-2 rating by Moody's or A-2 rating by Standard & Poor's", "label": "P2 or A2 [Member]", "terseLabel": "P-2 / A-2" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r218", "r305", "r341" ] }, "ifrs-full_PastServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PastServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Past service cost on defined benefit plans", "negatedLabel": "Past service cost" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PastServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails" ], "lang": { "en-us": { "role": { "label": "Past service cost, net defined benefit liability (asset)", "negatedLabel": "Past service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [domain]]" } } }, "auth_ref": [ "r26", "r250" ] }, "adxn_PatentMaintenanceAndRegistrationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PatentMaintenanceAndRegistrationCosts", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 5.0 }, "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "Patent maintenance and registration costs", "label": "Patent maintenance and registration costs", "terseLabel": "Patent maintenance and registration costs" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r450" ] }, "adxn_PayablesAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PayablesAccrualsAbstract", "lang": { "en-us": { "role": { "documentation": "Payables and accruals", "label": "Payables and accruals" } } }, "auth_ref": [] }, "adxn_PaymentDeferralPeriodForEquityIncentiveUnitsExercised": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PaymentDeferralPeriodForEquityIncentiveUnitsExercised", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment deferral period for equity incentive units exercised", "label": "Payment deferral period for equity incentive units exercised" } } }, "auth_ref": [] }, "adxn_PaymentsForCostsOnSaleAndExercisePreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PaymentsForCostsOnSaleAndExercisePreFundedWarrants", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for costs on sale and exercise of pre-funded warrants.", "label": "Payments for Costs on Sale and Exercise Pre-Funded Warrants", "negatedLabel": "Costs paid on exercise of pre-funded warrants" } } }, "auth_ref": [] }, "adxn_PaymentsForLegalFeesForDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PaymentsForLegalFeesForDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations", "weight": -1.0, "order": 2.0 }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow from legal fees incurred for the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations.", "label": "Payments for Legal Fees for Disposal of Noncurrent Assets Or Disposal Groups Classified As Held For Sale And Discontinued Operations", "negatedLabel": "Legal fees paid for Neurosterix Transaction" } } }, "auth_ref": [] }, "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails" ], "lang": { "en-us": { "role": { "label": "Payments from plan, net defined benefit liability (asset)", "terseLabel": "Benefits paid/deposited" } }, "en": { "role": { "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r28", "r251" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations", "weight": -1.0, "order": 1.0 }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedTerseLabel": "Principal element of lease payment" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r364" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r460" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r460" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r452" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r469" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r462" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r451" ] }, "adxn_PercentageOfCapitalAndInterestGuarantee": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PercentageOfCapitalAndInterestGuarantee", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of capital and interest guarantee", "label": "Percentage of capital and interest guarantee", "terseLabel": "Percentage of capital and interest guarantee" } } }, "auth_ref": [] }, "adxn_PercentageOfCashAndCashEquivalents": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PercentageOfCashAndCashEquivalents", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of cash and cash equivalents", "label": "Percentage of cash and cash equivalents", "terseLabel": "Percentage of cash and cash equivalents" } } }, "auth_ref": [] }, "adxn_PercentageOfContributionsByEmployee": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PercentageOfContributionsByEmployee", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of contributions by employee", "label": "Percentage of contributions by employee", "terseLabel": "Percentage of contributions by employee" } } }, "auth_ref": [] }, "adxn_PercentageOfContributionsByEmployer": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PercentageOfContributionsByEmployer", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of contributions by employer", "label": "Percentage of contributions by employer", "terseLabel": "Percentage of contributions by employer" } } }, "auth_ref": [] }, "adxn_PercentageOfCurrencyTransactionsEconomicallyHedged": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PercentageOfCurrencyTransactionsEconomicallyHedged", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of currency transactions economically hedged", "label": "Percentage of currency transactions economically hedged", "terseLabel": "Percentage of currency transactions economically hedged" } } }, "auth_ref": [] }, "adxn_PercentageOfEquityInterestReceived": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PercentageOfEquityInterestReceived", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Percentage of equity interest received", "label": "Percentage of equity interest received" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleDecreaseInActuarialAssumption", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of reasonably possible decrease in actuarial assumption", "negatedLabel": "Percentage of reasonably possible decrease in actuarial assumption" } }, "en": { "role": { "documentation": "The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r31" ] }, "adxn_PercentageOfReasonablyPossibleDecreaseInRiskAssumption": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PercentageOfReasonablyPossibleDecreaseInRiskAssumption", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of reasonably possible decrease in risk assumption", "label": "Percentage of reasonably possible decrease in risk assumption", "negatedLabel": "Percentage of reasonably possible decrease in risk assumption" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of reasonably possible decrease in unobservable input" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of assets." } } }, "auth_ref": [ "r538" ] }, "adxn_PercentageOfReasonablyPossibleDecreaseInVolatilityAssumption": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PercentageOfReasonablyPossibleDecreaseInVolatilityAssumption", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of reasonably possible decrease in volatility assumption", "label": "Percentage of reasonably possible decrease in volatility assumption", "negatedLabel": "Percentage of reasonably possible decrease in volatility assumption" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of reasonably possible increase in actuarial assumption", "terseLabel": "Percentage of reasonably possible increase in actuarial assumption" } }, "en": { "role": { "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r31" ] }, "adxn_PercentageOfReasonablyPossibleIncreaseInRiskAssumption": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PercentageOfReasonablyPossibleIncreaseInRiskAssumption", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of reasonably possible increase in risk assumption", "label": "Percentage of reasonably possible increase in risk assumption", "terseLabel": "Percentage of reasonably possible increase in risk assumption" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of reasonably possible increase in unobservable input" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of assets." } } }, "auth_ref": [ "r538" ] }, "adxn_PercentageOfReasonablyPossibleIncreaseInVolatilityAssumption": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PercentageOfReasonablyPossibleIncreaseInVolatilityAssumption", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of reasonably possible increase in volatility assumption", "label": "Percentage of reasonably possible increase in volatility assumption", "terseLabel": "Percentage of reasonably possible increase in volatility assumption" } } }, "auth_ref": [] }, "adxn_PeriodOfReasonablyPossibleDecreaseInActuarialAssumption": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PeriodOfReasonablyPossibleDecreaseInActuarialAssumption", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of reasonably possible decrease in actuarial assumption", "label": "Period of reasonably possible decrease in actuarial assumption", "terseLabel": "Period of reasonably possible decrease in actuarial assumption" } } }, "auth_ref": [] }, "adxn_PeriodOfReasonablyPossibleIncreaseInActuarialAssumption": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PeriodOfReasonablyPossibleIncreaseInActuarialAssumption", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of reasonably possible increase in actuarial assumption", "label": "Period of reasonably possible increase in actuarial assumption", "terseLabel": "Period of reasonably possible increase in actuarial assumption" } } }, "auth_ref": [] }, "adxn_PhantomSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PhantomSharesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Phantom shares", "label": "Phantom shares" } } }, "auth_ref": [] }, "adxn_PhantomSharesReceivedOnInvestment": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PhantomSharesReceivedOnInvestment", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Phantom shares received on investment", "label": "Phantom shares received on investment", "terseLabel": "Phantom shares received on investment in Stalicla SA" } } }, "auth_ref": [] }, "ifrs-full_PlanAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PlanAssetsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of plan assets", "terseLabel": "Fair value of plan assets" } }, "en": { "role": { "documentation": "This member stands for defined benefit plan assets. Plan assets comprise: (a) assets held by a long-term employee benefit fund; and (b) qualifying insurance policies." } } }, "auth_ref": [ "r19", "r244" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r453" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r509" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r452" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureStaffCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense, defined benefit plans", "negatedLabel": "Net gain on pension", "negatedTotalLabel": "Company pension amount", "terseLabel": "Retirement benefit (note 15)" } } }, "auth_ref": [ "r515", "r525" ] }, "ifrs-full_PreferenceSharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PreferenceSharesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Preference shares [member]", "terseLabel": "Preferred shares" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r551" ] }, "adxn_PreferredSharesReceivedOnInvestment": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PreferredSharesReceivedOnInvestment", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares received on investment", "label": "Preferred shares received on investment", "terseLabel": "Preferred shares received on investment in Stalicla SA" } } }, "auth_ref": [] }, "ifrs-full_PresentValueOfDefinedBenefitObligationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PresentValueOfDefinedBenefitObligationMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Defined benefit obligation", "terseLabel": "Defined benefit obligation" } }, "en": { "role": { "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods." } } }, "auth_ref": [ "r20", "r245" ] }, "ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations", "terseLabel": "Consideration from Neurosterix Transaction" } }, "en": { "role": { "documentation": "The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]" } } }, "auth_ref": [ "r532" ] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants", "terseLabel": "Proceeds from the exercise of pre-funded warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r533" ] }, "adxn_ProceedsFromGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ProceedsFromGrants", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from grants", "label": "Proceeds from grants", "terseLabel": "Proceeds from grants" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSaleOrIssueOfTreasuryShares", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale or issue of treasury shares", "terseLabel": "Sale of treasury shares", "verboseLabel": "Gross proceeds from sale of treasury shares" } }, "en": { "role": { "documentation": "The cash inflow from the sale or issuing of treasury shares. [Refer: Sale or issue of treasury shares; Treasury shares]" } } }, "auth_ref": [ "r533" ] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r194", "r371", "r385" ] }, "ifrs-full_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [domain]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r194", "r371", "r385" ] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 6.0 }, "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Professional fees" } } }, "auth_ref": [ "r547" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 17.0 }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net profit / (loss) for the period", "totalLabel": "Net profit / (loss) for the period", "verboseLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r92", "r94", "r189", "r191", "r265", "r282", "r317", "r346", "r368", "r373" ] }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share", "terseLabel": "Profit (loss), attributable to ordinary equity holders of parent entity - basic" } }, "en": { "role": { "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r58" ] }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share", "terseLabel": "Profit (loss), attributable to ordinary equity holders of parent entity - diluted" } }, "en": { "role": { "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r58" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails": { "parentTag": "adxn_ProfitLossFromOrdinaryActivitiesOfDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossFromContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureTaxesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) before tax", "terseLabel": "Net loss before tax", "totalLabel": "Net loss before tax from continuing operations", "verboseLabel": "Net gain / (loss) before tax" } } }, "auth_ref": [ "r163", "r383", "r384", "r391", "r392" ] }, "adxn_ProfitLossBeforeTaxDiscontinuedOperationsIncludingGainLossOnDiscontinuance": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ProfitLossBeforeTaxDiscontinuedOperationsIncludingGainLossOnDiscontinuance", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Profit (loss) before tax, discontinued operations including gain (loss) on discontinuance", "label": "Profit (loss) before tax, discontinued operations including gain (loss) on discontinuance", "terseLabel": "Net gain / (loss) before tax of discontinued operations" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from continuing operations", "totalLabel": "Net loss from continuing operations" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]" } } }, "auth_ref": [ "r104", "r189", "r191", "r346" ] }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share", "terseLabel": "Net loss from continuing operations - basic" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss) from continuing operations]" } } }, "auth_ref": [ "r58" ] }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share", "terseLabel": "Net loss from continuing operations - diluted" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss) from continuing operations]" } } }, "auth_ref": [ "r58" ] }, "ifrs-full_ProfitLossFromDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromDiscontinuedOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from discontinued operations", "terseLabel": "Net profit / (loss) from discontinued operations (attributable to equity holders of the Group)", "totalLabel": "Total net gain / (loss) from Discontinued operations", "verboseLabel": "Net profit / (loss) from discontinued operations" } } }, "auth_ref": [ "r105", "r162", "r352", "r355" ] }, "ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from discontinued operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share", "terseLabel": "Net profit from discontinued operations - basic" } } }, "auth_ref": [ "r58" ] }, "ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from discontinued operations attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share", "terseLabel": "Net profit from discontinued operations - diluted" } } }, "auth_ref": [ "r58" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating loss" } } }, "auth_ref": [ "r362", "r552" ] }, "adxn_ProfitLossFromOrdinaryActivitiesOfDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ProfitLossFromOrdinaryActivitiesOfDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_ProfitLossFromDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of profit (loss) from ordinary activities of discontinued operations after tax expense or income.", "label": "Profit Loss From Ordinary Activities Of Discontinued Operations Net Of Tax", "totalLabel": "Net loss from discontinued operations" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment", "periodEndLabel": "Closing amount", "periodStartLabel": "Opening amount", "verboseLabel": "Equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r13", "r241", "r325" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Equipment." } } }, "auth_ref": [] }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInAssociate", "presentation": [ "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesConsolidationAndSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in associate", "terseLabel": "Equity interest held", "verboseLabel": "Equity interest received" } }, "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r50", "r52", "r96" ] }, "adxn_PurchaseOfDerivativeFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PurchaseOfDerivativeFinancialInstruments", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Purchase of derivative financial instruments", "label": "Purchase of derivative financial instruments", "negatedLabel": "Investment in Stalicla SA - derivative financial instruments" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of financial assets measured at fair value through other comprehensive income, classified as investing activities", "negatedLabel": "Investment in Stalicla SA - preferred shares" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of financial assets measured at fair value through other comprehensive income, classified as investing activities." } } }, "auth_ref": [ "r532" ] }, "adxn_PurchaseOfInvestmentsInOtherEntitiesIncludingRelatedFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "PurchaseOfInvestmentsInOtherEntitiesIncludingRelatedFinancialInstruments", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase of investments in other entities, including related financial instruments", "label": "Purchase of investments in other entities, including related financial instruments", "terseLabel": "Investment in Stalicla SA", "verboseLabel": "Subscription price for investment in Stalicla SA" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsCashFlowOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Purchase of property, plant and equipment", "terseLabel": "Capital expenditure" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r363" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r450" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r450" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r85", "r118", "r139", "r154", "r223", "r369", "r370", "r543" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r85", "r118", "r139", "r154", "r223", "r369", "r370", "r543" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r154" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]" } } }, "auth_ref": [ "r154" ] }, "ifrs-full_RawMaterialsAndConsumablesUsed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RawMaterialsAndConsumablesUsed", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsOperatingCostsOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials and consumables used", "terseLabel": "Laboratory consumables" } } }, "auth_ref": [ "r356", "r391" ] }, "ifrs-full_RealEstatePercentageContributedToFairValueOfPlanAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RealEstatePercentageContributedToFairValueOfPlanAssets", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails": { "parentTag": "adxn_AllAssetsPercentageContributedToFairValueOfPlanAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Real estate, percentage contributed to fair value of plan assets", "terseLabel": "Real estate" } }, "en": { "role": { "documentation": "The percentage real estate contributes to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [domain]] [Contrast: Real estate, amount contributed to fair value of plan assets]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_ReceivablesFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReceivablesFromContractsWithCustomers", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Receivables from contracts with customers", "terseLabel": "Trade receivable" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due." } } }, "auth_ref": [ "r119", "r122", "r201" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r417", "r428", "r438", "r471" ] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related party transactions" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsFinancialPerformanceOfDiscontinuedOperationsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development" } } }, "auth_ref": [ "r73", "r275" ] }, "adxn_ResearchAndDevelopmentExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ResearchAndDevelopmentExpensesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Research and development expenses", "label": "Research and development expenses [member]", "terseLabel": "Research and development expense" } } }, "auth_ref": [] }, "adxn_ResearchFundingPaidByInvestorToThirdParties": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ResearchFundingPaidByInvestorToThirdParties", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Research funding paid by investor to third parties", "label": "Research funding paid by investor to third parties", "terseLabel": "Research funding paid by investor to third parties" } } }, "auth_ref": [] }, "adxn_ResearchFundingReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ResearchFundingReceived", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Research funding received", "label": "Research funding received", "terseLabel": "Research funding received" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Translation Reserve" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r38", "r257", "r393" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r418", "r429", "r439", "r472" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r419", "r430", "r440", "r473" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r426", "r437", "r447", "r480" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated deficit" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r390", "r396", "r397" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r320", "r393" ] }, "adxn_RetirementBenefitObligationOfEmployeesLeavingDueToDisposalOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "RetirementBenefitObligationOfEmployeesLeavingDueToDisposalOfDiscontinuedOperation", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails": { "parentTag": "adxn_DisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsConsideration", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Retirement benefit obligation of employees leaving due to disposal of discontinued operation", "label": "Retirement benefit obligation of employees leaving due to disposal of discontinued operation", "terseLabel": "Retirement benefit obligation of employees leaving the Group (IAS 19)", "verboseLabel": "Past service cost due to transfer of employees" } } }, "auth_ref": [] }, "ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails": { "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsContributionsAndFundingDetails" ], "lang": { "en-us": { "role": { "label": "Return on plan assets excluding interest income or expense, net of tax, defined benefit plans", "terseLabel": "Actuarial loss on plan assets" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from the return on plan assets, excluding amounts included in interest expense (income) arising from defined benefit plans. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitObligationsMovementDetails" ], "lang": { "en-us": { "role": { "label": "Return on plan assets excluding interest income or expense, net defined benefit liability (asset)", "terseLabel": "Plan assets loss" } }, "en": { "role": { "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [domain]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]" } } }, "auth_ref": [ "r24", "r249" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "Income" } } }, "auth_ref": [ "r103", "r163", "r185", "r190", "r194", "r195", "r197", "r349", "r368", "r391", "r392" ] }, "ifrs-full_RevenueAndOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAndOperatingIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue and other operating income", "totalLabel": "Revenue and other operating income" } } }, "auth_ref": [ "r552" ] }, "adxn_RevenueFromCollaborativeResearchFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "RevenueFromCollaborativeResearchFunding", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue from collaborative research funding", "label": "Revenue from collaborative research funding", "terseLabel": "Collaborative research funding" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue from contract with customer" } } }, "auth_ref": [ "r120", "r121", "r200" ] }, "adxn_RevenueFromContractsWithCustomersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "RevenueFromContractsWithCustomersAbstract", "lang": { "en-us": { "role": { "documentation": "Revenue from contracts with customers", "label": "Revenue from contract with customer" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails" ], "lang": { "en-us": { "role": { "label": "Interest income", "terseLabel": "Interests income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r108", "r186", "r193", "r547" ] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets.", "periodEndLabel": "Closing amount", "periodStartLabel": "Opening amount", "terseLabel": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r126", "r132", "r207" ] }, "adxn_RightsGrantedMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "RightsGrantedMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Rights granted", "label": "Rights granted", "terseLabel": "Rights granted" } } }, "auth_ref": [] }, "adxn_RiskFreeInterestRateAssumptionHighAmount": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "RiskFreeInterestRateAssumptionHighAmount", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Risk free interest rate assumption, high amount", "label": "Risk free interest rate assumption, high amount", "terseLabel": "Risk free interest rate assumption, high amount" } } }, "auth_ref": [] }, "adxn_RiskFreeInterestRateAssumptionLowAmount": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "RiskFreeInterestRateAssumptionLowAmount", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Risk free interest rate assumption, low amount", "label": "Risk free interest rate assumption, low amount", "terseLabel": "Risk free interest rate assumption, low amount" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r489" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r489" ] }, "adxn_SaleOfTreasuryShare": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "SaleOfTreasuryShare", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Sale of treasury shares", "label": "Sale of treasury share", "terseLabel": "Sale of treasury shares" } } }, "auth_ref": [] }, "adxn_SaleOfTreasuryShares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "SaleOfTreasuryShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale of treasury shares", "label": "Sale of treasury shares" } } }, "auth_ref": [] }, "adxn_SalePriceOfSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "SalePriceOfSharesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for sale price of shares", "label": "Sale price of shares" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r399" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r401" ] }, "adxn_ServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ServiceAgreementMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a class of intangible assets representing service agreements.", "label": "Service Agreement [Member]", "terseLabel": "Service agreement" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "adxn_ShareCapitalAsRegisteredInTradeRegister": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ShareCapitalAsRegisteredInTradeRegister", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Share capital as registered in trade register", "label": "Share capital as registered in commercial register" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share issue related cost", "negatedLabel": "Cost of treasury shares issuance" } } }, "auth_ref": [ "r546" ] }, "adxn_ShareOfNetAssetsOfAssociates": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ShareOfNetAssetsOfAssociates", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of reporting entity's share of net assets of associates", "label": "Share of net assets of associates", "terseLabel": "Group share of net assets" } } }, "auth_ref": [] }, "ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Share of other comprehensive income of associates and joint ventures accounted for using equity method that will not be reclassified to profit or loss, net of tax", "terseLabel": "Share of other comprehensive loss of investments accounted for using the equity method", "verboseLabel": "Share of other comprehensive gain / (loss) of Neurosterix's Group" } }, "en": { "role": { "documentation": "Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will not be reclassified to profit or loss, net of tax." } } }, "auth_ref": [ "r353" ] }, "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Share of net loss of associates", "terseLabel": "Share of net loss of investments accounted for using the equity method", "verboseLabel": "Share of net loss of Neurosterix's Group" } } }, "auth_ref": [ "r552" ] }, "adxn_ShareOptionExercisePriceChf0.043Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ShareOptionExercisePriceChf0.043Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Share Option Exercise Price CHF0.043.", "label": "Strike Price CHF 0.043" } } }, "auth_ref": [] }, "adxn_ShareOptionExercisePriceChf0.043To0.106Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ShareOptionExercisePriceChf0.043To0.106Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Option Exercise Price CHF0.043 to 0.106", "label": "Strike Price CHF 0.043 to 0.106" } } }, "auth_ref": [] }, "adxn_ShareOptionExercisePriceChf0.13Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ShareOptionExercisePriceChf0.13Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Option Exercise Price CHF0.13", "label": "Strike Price CHF 0.13" } } }, "auth_ref": [] }, "adxn_ShareOptionExercisePriceChf0.14ToChf0.99Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ShareOptionExercisePriceChf0.14ToChf0.99Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Option Exercise Price CHF0.14 to CHF0.99", "label": "Strike Price CHF 0.14 to 0.99" } } }, "auth_ref": [] }, "adxn_ShareOptionExercisePriceChf1.00To3.00Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ShareOptionExercisePriceChf1.00To3.00Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Option Exercise Price CHF1.00 to 3.00", "label": "Strike Price CHF 1.00 to 3.00" } } }, "auth_ref": [] }, "ifrs-full_ShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOptionsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share option plans", "verboseLabel": "Share options" } }, "en": { "role": { "documentation": "This member stands for share options." } } }, "auth_ref": [ "r528" ] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Share premium.", "terseLabel": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r390", "r396" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share Premium" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r320" ] }, "adxn_ShareSalePrice": { "xbrltype": "perShareItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ShareSalePrice", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Share sale price", "label": "Share sale price", "terseLabel": "Share sale price" } } }, "auth_ref": [] }, "adxn_SharesHeldInTreasuryMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "SharesHeldInTreasuryMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares held in treasury", "label": "Treasury share [member]", "terseLabel": "Treasury shares" } } }, "auth_ref": [] }, "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares in entity held by entity or by its subsidiaries or associates", "negatedPeriodEndLabel": "Number of shares at end of period", "negatedPeriodStartLabel": "Number of shares at beginning of period", "terseLabel": "Number of treasury shares" } }, "en": { "role": { "documentation": "The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Total for all associates [member]; Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r220", "r307", "r343" ] }, "adxn_SharesNotSubjectToSalesRestrictions": { "xbrltype": "decimalItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "SharesNotSubjectToSalesRestrictions", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares not subject to sales restrictions", "label": "Shares not subject to sales restrictions" } } }, "auth_ref": [] }, "adxn_SharesRelatedToEmployeesAndExecutiveManagersTransferredOnDisposalOfOperations": { "xbrltype": "decimalItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "SharesRelatedToEmployeesAndExecutiveManagersTransferredOnDisposalOfOperations", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares related to employees and Executive Managers transferred on disposal of operations", "label": "Shares related to employees and Executive Managers transferred on disposal of operations" } } }, "auth_ref": [] }, "adxn_SignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "SignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "documentation": "Material accounting policies", "label": "Summary of material accounting policies" } } }, "auth_ref": [] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesConsolidationAndSegmentsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r51", "r53", "r111", "r300" ] }, "ifrs-full_SignificantInvestmentsInAssociatesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInAssociatesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsDetailsOfNetGainOfSaleOfActivitiesDetails", "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesConsolidationAndSegmentsDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Associates [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r51", "r53", "r111", "r300" ] }, "ifrs-full_SignificantUnobservableInputAssets": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantUnobservableInputAssets", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Significant unobservable input, assets", "terseLabel": "Significant unobservable input" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of assets." } } }, "auth_ref": [ "r114" ] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureStaffCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureStaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Social security contributions", "terseLabel": "Social charges and insurances" } } }, "auth_ref": [ "r527" ] }, "adxn_StaliclaSaMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "StaliclaSaMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Stalicla SA", "label": "Stalicla SA" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Changes in Equity" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]", "verboseLabel": "Consolidated Statements of Changes in Equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r320" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Comprehensive Profit or Loss" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r421", "r432", "r442", "r475" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "adxn_StrikePriceOfEquityIncentiveUnits": { "xbrltype": "perShareItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "StrikePriceOfEquityIncentiveUnits", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Strike price of equity incentive units", "label": "Strike price of equity incentive units", "terseLabel": "Strike price of options" } } }, "auth_ref": [] }, "adxn_StrikePriceOfWarrantsReceivedOnInvestment": { "xbrltype": "perShareItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "StrikePriceOfWarrantsReceivedOnInvestment", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Strike price of warrants received on investment", "label": "Strike price of warrants received on investment in Stalicla SA" } } }, "auth_ref": [] }, "adxn_SubsequentPeriodOfCurrencyTransactionsEconomicallyHedged": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "SubsequentPeriodOfCurrencyTransactionsEconomicallyHedged", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Subsequent period of currency transactions economically hedged", "label": "Subsequent period of currency transactions economically hedged", "terseLabel": "Subsequent period of currency transactions economically hedged" } } }, "auth_ref": [] }, "ifrs-full_SurplusDeficitInPlan": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SurplusDeficitInPlan", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Surplus (deficit) in plan", "terseLabel": "Funded status" } }, "en": { "role": { "documentation": "The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]" } } }, "auth_ref": [ "r526" ] }, "adxn_SwissLifeMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "SwissLifeMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "documentation": "Swiss Life", "label": "Swiss Life", "terseLabel": "Swiss Life" } } }, "auth_ref": [] }, "adxn_TabularDisclosureOfInformationAboutFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "TabularDisclosureOfInformationAboutFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income.", "label": "Tabular disclosure Of Information About Financial Assets At Fair Value Through Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of investments at fair value through Other Comprehensive Income (OCI)" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r468" ] }, "adxn_TaxEffectFromFinancialIncomeFromSaleOfTreasurySharesBySubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "TaxEffectFromFinancialIncomeFromSaleOfTreasurySharesBySubsidiary", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to recognition of financial income in financial statements on sale of treasury shares by subsidiary.", "label": "Tax Effect from Financial Income from Sale of Treasury Shares by Subsidiary", "negatedLabel": "Sale of treasury shares by a subsidiary, recognized as financial loss / (income) in standalone financial statements" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)", "negatedLabel": "Expenses not deductible for tax purposes" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r232" ] }, "adxn_TaxEffectOfExpensesChargedAgainstEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "TaxEffectOfExpensesChargedAgainstEquity", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax effect of expenses charged against equity", "label": "Tax effect of expenses charged against equity", "negatedLabel": "Deductible expenses charged against equity for issuance of shares" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfForeignTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfForeignTaxRates", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax effect of foreign tax rates", "negatedLabel": "Effect of different tax rates in USA and France" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r232" ] }, "adxn_TaxEffectOfPermanentDifferencesRelatedToInvestmentsAccountedUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "TaxEffectOfPermanentDifferencesRelatedToInvestmentsAccountedUsingEquityMethod", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to permanent differences related to investments accounted for using the equity method.", "label": "Tax Effect of Permanent Differences Related to Investments Accounted Using the equity Method", "negatedLabel": "Difference related to investments accounted for using the equity method" } } }, "auth_ref": [] }, "adxn_TaxEffectOfProfitsLossOfSubsidiaryOnLossOfControl": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "TaxEffectOfProfitsLossOfSubsidiaryOnLossOfControl", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to profit (loss) of subsidiary on loss of control.", "label": "Tax Effect of Profits (Loss) of Subsidiary on Loss of Control", "negatedLabel": "Net loss incurred by Neurosterix Pharma Srl from March 19 2024 to April 1, 2024 1" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfTaxLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfTaxLosses", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax effect of tax losses", "negatedLabel": "Total tax not recognized as deferred tax (asset) / liability" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r232" ] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax expense (income) at applicable tax rate", "negatedLabel": "Tax calculated at a tax rate of 14.7% for 2024 and 2025 (13.99% for 2023)" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r3", "r232" ] }, "adxn_TaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "TaxesAbstract", "lang": { "en-us": { "role": { "documentation": "Taxes", "label": "Taxes" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r85", "r118", "r139", "r154", "r223", "r369", "r370", "r543" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r460" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r467" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Payables and accruals", "totalLabel": "Total payables and accruals" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAndAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r394", "r550" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 3.0 }, "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Trade and other receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r312", "r328", "r339" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r488" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r490" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r491" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r492" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r492" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r490" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r490" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r493" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r491" ] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "http://addextherapeutics.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Treasury shares", "negatedLabel": "Treasury shares reserve" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r54", "r390", "r396" ] }, "ifrs-full_TreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasurySharesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "http://addextherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Shares Reserve" } }, "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r320" ] }, "adxn_TreasurySharesSoldOtherThanUnderSaleAgencyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "TreasurySharesSoldOtherThanUnderSaleAgencyAgreementMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Treasury shares sold, other than under sale agency agreement", "label": "Treasury shares sold not under sale agency agreement" } } }, "auth_ref": [] }, "adxn_TreasurySharesSoldUnderSaleAgencyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "TreasurySharesSoldUnderSaleAgencyAgreementMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Treasury shares sold, under sale agency agreement", "label": "Treasury shares sold under sale agency agreement" } } }, "auth_ref": [] }, "adxn_TypeOfTreasuryShareTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "TypeOfTreasuryShareTransactionAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of treasury share transaction", "label": "Type of treasury share transaction [Axis]" } } }, "auth_ref": [] }, "adxn_TypeOfTreasuryShareTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "TypeOfTreasuryShareTransactionDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of treasury share transaction", "label": "Type of treasury share transaction [domain]" } } }, "auth_ref": [] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r40", "r140", "r141", "r142", "r144", "r169", "r172", "r173", "r259" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r40", "r140", "r141", "r142", "r144", "r169", "r172", "r173", "r259" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r155", "r290" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingDspppDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOutstandingEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r155", "r290" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States of America" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "USD", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "http://addextherapeutics.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "USD", "terseLabel": "USD" } } }, "auth_ref": [] }, "adxn_UnderlyingSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "UnderlyingSharePriceMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for underlying share price", "label": "Underlying share price" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r487" ] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r114", "r539" ] }, "ifrs-full_UnobservableInputsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [domain]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r114", "r539" ] }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "presentation": [ "http://addextherapeutics.com/role/DisclosureTaxesTaxLossDetails" ], "lang": { "en-us": { "role": { "label": "Unused tax losses for which no deferred tax asset recognised", "terseLabel": "Unrecorded tax losses carry forwards" } }, "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } } }, "auth_ref": [ "r5", "r234" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://addextherapeutics.com/role/DisclosureSummaryOfMaterialAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Estimated useful life" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r9", "r237" ] }, "adxn_ValueOfIssuedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "ValueOfIssuedWarrants", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of issued warrants", "label": "Value of warrants" } } }, "auth_ref": [] }, "adxn_VariableConsiderationAllocatedToContract": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "VariableConsiderationAllocatedToContract", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Variable consideration allocated to contract", "label": "Variable consideration allocated to contract", "terseLabel": "Variable consideration allocated to contract" } } }, "auth_ref": [] }, "adxn_VestingPeriodOfOptionsGranted": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "VestingPeriodOfOptionsGranted", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Vesting period of options granted", "label": "Vesting period of options granted" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r456" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureStaffCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureStaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries", "terseLabel": "Wages and salaries" } } }, "auth_ref": [ "r527" ] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [member]", "terseLabel": "Warrants" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r528" ] }, "adxn_WarrantsReceivedOnInvestment": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "WarrantsReceivedOnInvestment", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants received on investment", "label": "Warrants received on investment", "terseLabel": "Warrants received on investment in Stalicla SA" } } }, "auth_ref": [] }, "adxn_WarrantsReceivedOnInvestmentsClassOneMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "WarrantsReceivedOnInvestmentsClassOneMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants received on investments, class one", "label": "Warrants received with ten-year exercise period" } } }, "auth_ref": [] }, "adxn_WarrantsReceivedOnInvestmentsClassTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "WarrantsReceivedOnInvestmentsClassTwoMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants received on investments, class two", "label": "Warrants received with five-year exercise period" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement", "terseLabel": "Forfeited" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r540" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement", "terseLabel": "Granted" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r540" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansDspppDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Average subscription price / floor price / deferred strike price at end of period", "periodStartLabel": "Average subscription price / floor price / deferred strike price at beginning of period" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r540" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement", "terseLabel": "Average strike price of exercisable options" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r152", "r288" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options exercised in share-based payment arrangement", "terseLabel": "Exercised" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r150", "r286" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement", "terseLabel": "Forfeited" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r149", "r285" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "verboseLabel": "Granted" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r148", "r284" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r147", "r151", "r283", "r287" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, share options granted", "terseLabel": "Weighted average fair value of share options granted" } }, "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r157" ] }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsPlansAssumptionsEsopDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price, share options granted", "terseLabel": "Weighted average share price per share at the grant date" } }, "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } } }, "auth_ref": [ "r156" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares outstanding", "verboseLabel": "Weighed average number of shares in issue - basic" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r59" ] }, "adxn_Year2018Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "Year2018Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "2018", "label": "2018", "terseLabel": "2018" } } }, "auth_ref": [] }, "adxn_Year2021Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "Year2021Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Year 2021", "label": "2021", "terseLabel": "2021" } } }, "auth_ref": [] }, "adxn_Year2022Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "Year2022Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Year 2022", "label": "2022", "terseLabel": "2022" } } }, "auth_ref": [] }, "adxn_Year2023Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "Year2023Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionPlansEsopDetails" ], "lang": { "en-us": { "role": { "documentation": "Year 2023.", "label": "Year 2023 [Member]", "terseLabel": "2023" } } }, "auth_ref": [] }, "adxn_Year2026Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "Year2026Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "2026", "label": "Year 2026 [Member]", "terseLabel": "2026" } } }, "auth_ref": [] }, "adxn_Years2021To2023Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20251231", "localname": "Years2021To2023Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureProfitOrLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Years 2021 to 2023", "label": "Years 2021 to 2023 [member]", "terseLabel": "2021-2023" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r454" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_a&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_b&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_d&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_f&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_g&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "145", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145_a&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_b&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "148", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_148_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_c&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "86", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86_a&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "89", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_89&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_46&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "2", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_2_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_c&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "58", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_58&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_c&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "38", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_38&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Section": "Presentation and disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_h&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "105", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_105_a&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_a&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_c&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_f&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_b&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "128", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "170", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_170&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "178", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "180", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_180_b&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "182", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_182&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_e&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "204", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_a&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_b&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_c&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_d&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_f&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "208", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_208&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "210", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_210&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "211", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_211_b&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "216", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_216_a&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_c&doctype=Standard", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_b&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231_f&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "250", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_250&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "259", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259_a&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "260", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_260&doctype=Standard", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "34", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard", "URIDate": "2025-03-27" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_a&doctype=Standard", "URIDate": "2025-03-27" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_e&doctype=Standard", "URIDate": "2025-03-27" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_c&doctype=Standard", "URIDate": "2025-03-27" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "88", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard", "URIDate": "2025-03-27" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_vi&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B15", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B15&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "11A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-b&anchor=para_11A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard", "URIDate": "2025-03-27" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_d&doctype=Standard", "URIDate": "2025-03-27" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "ea", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_ea&doctype=Standard", "URIDate": "2025-03-27" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard", "URIDate": "2025-03-27" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_e&doctype=Standard", "URIDate": "2025-03-27" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r357": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2025-03-27" }, "r358": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_b&doctype=Standard", "URIDate": "2025-03-27" }, "r359": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2025-03-27" }, "r360": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r361": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r362": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r363": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r364": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r365": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2025-03-27" }, "r366": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2025-03-27" }, "r367": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r368": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r369": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r370": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r371": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r372": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r373": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r374": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r375": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r376": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r377": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r378": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r379": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r380": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r381": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG20C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r382": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r383": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r384": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r385": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard", "URIDate": "2025-03-27" }, "r386": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r387": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "191", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_191_f&doctype=Standard", "URIDate": "2025-03-27" }, "r388": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r389": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r390": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r391": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r392": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r393": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r394": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r395": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r396": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r397": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r398": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r399": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r400": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r404": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r405": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r406": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r407": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r408": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r409": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r410": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r411": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r412": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r413": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r414": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r415": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r416": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r417": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r418": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r419": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r420": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r421": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r422": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r423": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r424": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r425": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r445": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r446": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r447": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r448": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2025-03-27" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142_a&doctype=Standard", "URIDate": "2025-03-27" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142_b&doctype=Standard", "URIDate": "2025-03-27" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142_c&doctype=Standard", "URIDate": "2025-03-27" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142_d&doctype=Standard", "URIDate": "2025-03-27" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142_e&doctype=Standard", "URIDate": "2025-03-27" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142_g&doctype=Standard", "URIDate": "2025-03-27" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard", "URIDate": "2025-03-27" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145&doctype=Standard", "URIDate": "2025-03-27" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_5&doctype=Standard", "URIDate": "2025-03-27" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2025-03-27" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2025-03-27" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_c&doctype=Standard", "URIDate": "2025-03-27" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_d&doctype=Standard", "URIDate": "2025-03-27" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }